###begin article-title 0
2007 Annual progress report synopsis of the Center for Structures of Membrane Proteins
###end article-title 0
###begin p 1
A synopsis of the 2007 annual progress report for the Center for Structures of Membrane Proteins, a specialized center of the Protein Structure Initiative.
###end p 1
###begin title 2
Keywords
###end title 2
###begin title 3
Mission of the CSMP research center ()
###end title 3
###begin p 4
###xml 1070 1075 <span type="species:ncbi:9606">human</span>
###xml 1090 1095 <span type="species:ncbi:9606">human</span>
###xml 1159 1164 <span type="species:ncbi:9606">human</span>
###xml 1269 1274 <span type="species:ncbi:9606">human</span>
The goal of the Center for Structures of Membrane Proteins (CSMP) is to express, purify and determine the structures of representative members of membrane protein classes, aiming for coverage of membrane proteins of novel folds, and novel functions. Nearly 30% of all eukaryotic proteins are membrane proteins, and these include protein targets for over 40% of all drugs in use today. There is little understanding of the mechanisms and atomic interactions of any one of these. This is primarily because they are membrane proteins, where preparation in a structurally homogeneous and functionally active-state, and subsequent structure determination has been extremely challenging. Where classes of membrane proteins are represented in prokaryotes, it is likely that structures for a homolog will be determined first for prokaryotic or archaeal members, so target proteins will be first sought from these organisms. Our plan proposes structure determination of membrane protein targets with two or more membrane crossings, from prokaryotic, archaeal, extremeophile, and human genomes. Many human proteins have no good homologs in prokaryotes or archaea, thus human membrane targets are also included with the goal of coverage of the folds of the membrane proteome. The human genes are the only ones from a eukaryote, selected because their structures can instruct in structure-based drug design.
###end p 4
###begin title 5
Overall organization of the U54 research center
###end title 5
###begin p 6
CSMP () supports an integrated program aimed at facilitating the cloning, expression purification, crystallization, and structure determination of membrane proteins with the aim of coverage of the membrane proteome. The core capabilities provide for fermentation, cell culture, gene cloning, expression, protein purification, characterization, X-ray diffraction at the Advanced Light Source (ALS) in Berkeley, structure determination by 2-D electron microscopy, and structure determination by Nuclear Magnetic Resonance techniques (NMR).
###end p 6
###begin p 7
###xml 387 394 387 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 540 548 540 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli.</italic>
###xml 360 365 <span type="species:ncbi:9606">human</span>
###xml 387 394 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 540 547 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 705 710 <span type="species:ncbi:9606">human</span>
The executive council consists of the seven principal investigators. Delegated areas of responsibility include responsibility over the projects. Dr. Sali directs the effort in dynamic target selection, and also the final step in using structures determined in the Center to model the structures of homologs. Dr. Choe leads the effort to optimize expression of human membrane proteins in E. coli using the MISTIC system that he discovered. Dr. Stroud will manage the standardized effort to express bacterial and archeal membrane proteins in E. coli. Drs. Choe, Minor and Stroud will oversee the purification and characterization of proteins produced in their projects. In almost all cases, prokaryotic and human membrane protein targets are investigated through the CSMP and all the other eukaryotic membrane protein targets are investigated through MPEC. However, the funding of the MPEC center did not provide funds for crystallography or structure determination equipment or personnel. Therefore, promising eukaryotic membrane protein targets that move through the Stroud portion of the MPEC protein expression and purification pipeline to a pure, homogeneous, and stable preparation state are then incorporated into the CSMP crystallography and structure determination pipeline.
###end p 7
###begin p 8
The Principal Investigators derive from four institutions, all located in California. The institutions are UCSF (Stroud, Sali, Minor, and Holton), Salk Institute (Choe, Riek, and Kwiatkowski), UCDavis (Stahlberg), and UCLA (Kaback). The PIs and members of the team meet each week in televised conference (1.00 pm-3.00 pm each Tuesday) to present progress in rotation. After 1.5 years we held a self-evaluation to identify weak projects and to plan for any redirection of effort, and resources. Each aim will now be gauged by 3-monthly milestones that will be used to adjust direction and necessary funding. This will be reviewed annually to assure direction.
###end p 8
###begin title 9
The principal investigators
###end title 9
###begin p 10
The investigators are in close touch with each other via an intranet, phone, and direct contacts. The institutions are UCSF (Stroud, Sali, Minor, and Holton), Salk Institute (Choe, Riek, and Kwiatkowski), UCDavis (Stahlberg), and UCLA (Kaback). Each principal investigator has played a key role in the discovery of major membrane protein biology, and/or in the development of procedures to understand membrane proteins at the molecular level.
###end p 10
###begin p 11
Robert Stroud and his group have studied many membrane protein systems seeking characterizations and crystal structures. So far they have determined 7 high-resolution structures of membrane proteins at atomic resolution, one to 1.35 A resolution, currently the highest resolution of any membrane protein structure. They also report the mechanism of targeting membrane proteins to the endoplasmic reticulum membrane by the signal recognition particle and its receptor complex interaction.
###end p 11
###begin p 12
Dr. Andrej Sali is a leader in development of methods for protein structure analysis and prediction. He has played a key role in the New York Structural Genomix Research Consortium aimed at soluble proteins.
###end p 12
###begin p 13
###xml 220 227 220 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 220 227 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Senyon Choe's group has elucidated mechanisms of potassium channels from structure analysis of domains of these channels. Dr. Choe has pioneered the MISTIC method for production of membrane proteins from all species, in E. coli.
###end p 13
###begin p 14
Daniel Minor has also played a key role in understanding the regulation of potassium and calcium channels. He determined key structures that help elucidate the mechanisms of these channels. He has also developed schemes to test for membrane stability.
###end p 14
###begin p 15
Ronald Kaback is world renowned for his extensive studies of the Lactose permease. Over many years he has been a pioneer in membrane biology. Kaback recently was coauthored with Iwata of the high-resolution structure determination of the Lac permease. Thus his extensive mutational analysis of Lac permease is legendary and can now be interpreted.
###end p 15
###begin p 16
Henning Stahlberg is a world leader in electron and atomic force microscopy of membrane proteins. He beautifully elaborated the structures of the GlpF and other aquaporin channels in their membrane environment.
###end p 16
###begin p 17
Dr. Roland Riek is an inventor of TROSY and an expert in the use of NMR for three-dimensional structure determination focused on membrane proteins. He studied under the tutelage of Dr. Kurt Wuthrich.
###end p 17
###begin p 18
###xml 24 30 <span type="species:ncbi:9606">person</span>
Dr. James Holton (a key person at the ALS) is one of the world leaders in development of synchrotron and storage ring sources for high throughput X-ray diffraction. He has made fundamental contributions to the operations of beamline 8.3.1 that is currently the model for others as they come on line at the ALS. He is a highly innovative developer. For example he developed a robotic mounting system for crystals at beamline 8.3.1 for under $5,000.
###end p 18
###begin title 19
Scientific progress
###end title 19
###begin title 20
Progress in the development of new methods, technology, approaches, and ideas for protein production and structure determination
###end title 20
###begin p 21
###xml 417 422 <span type="species:ncbi:9606">human</span>
###xml 624 629 <span type="species:ncbi:9606">human</span>
This PSI Specialized Center focuses on membrane proteins. We target prokaryotic proteins expressed in prokaryotic organisms as the most amenable system for producing proper expression and targeting of these proteins to the cellular membranes. We believe that these will provide the most efficacious pathway to determining the structures of new membrane protein folds and proteins. We believe that archaebacterial and human membrane proteins provide an intermediate pathway to provide new folds and proteins since they may be evolutionarily intermediate between prokaryotic and eukaryotic membrane proteins. We also focus on human membrane proteins, while they represent the most technically difficult class of targets; they also have the highest potential value for structure based drug design. Finally, we use all of our skills and technology at our disposal to also target selected membrane protein complexes for expression and subsequent purification, crystallization, and structure determination.
###end p 21
###begin title 22
Molecular biology of selected targets
###end title 22
###begin p 23
###xml 14 21 14 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 48 49 48 49 <underline xmlns:xlink="http://www.w3.org/1999/xlink">L</underline>
###xml 57 58 57 58 <underline xmlns:xlink="http://www.w3.org/1999/xlink">I</underline>
###xml 69 70 69 70 <underline xmlns:xlink="http://www.w3.org/1999/xlink">C</underline>
###xml 14 21 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
With over 700 E. coli targets to modify for the Ligation Independent Cloning (LIC) method and test for proper insertion of the target gene into the various expression vectors, we were right on the border of being able to efficiently using medium to high throughput molecular biology as opposed to purely manual methods. Melissa Del Rosario was instrumental in developing methods and techniques for using vacuum manifold based techniques on 96 well plates. These techniques permitted the screening of 288 constructs/day and allowed the efficient incorporation of our target genes into a variety of expression vectors.
###end p 23
###begin title 24
Expression
###end title 24
###begin p 25
###xml 237 244 237 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 237 244 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
The initial bottleneck for determining structure is membrane protein expression. Expression in bacteria is being carried out utilizing a novel scheme developed and applied by Senyon Choe, termed MISTIC, and by standardized procedures in E. coli that have already yielded high-resolution membrane protein structures in the Stroud and Kaback laboratories. We are also using codon optimization to improve expression of non-native proteins in our expression host cells, and Cell-Free Synthesis to target proteins that resist in vivo expression methods.
###end p 25
###begin p 26
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human membrane proteins that are not expressed adequately or correctly folded by the above procedures will also be expressed through the NIH Roadmap Center directed by Stroud (GM-73210, Membrane Protein Expression Center, MPEC) funded in October 2004. The Membrane Protein Expression Center focuses specifically on developing novel methods for expression of eukaryotic (only) membrane proteins, and synergism with that center is expected to leverage results with this Structural Center.
###end p 26
###begin title 27
Purification and characterization
###end title 27
###begin p 28
###xml 979 984 <span type="species:ncbi:42554">Tetra</span>
Purification, solubilization and characterization are carried out as core functions at UCSF. The Protein Analysis Core at the Salk run by Kwiatkowski is developing High Throughput SELDI mass spectroscopy for molecular mass identification, NMR Analysis for detergent exchange, and ultracentrifugation to determine quaternary structure. As we approach the 4th year's operation of CSMP, many targets are emanating from the expression efforts and entering the Purification and Characterization cores. In our hands, automation of purification is still premature as an option for membrane proteins primarily because of the need for hand-tuned optimization of extraction, purification stability, and solubility, in which each step involves screening many different detergents. Thus, as our expression pipeline is becoming efficient, protein purification to a pure homogeneous and stable form is the current bottleneck. We have addressed this bottleneck by setting up 5 HPLC stations, 2 Tetra Detector HPLC Analysis stations and 5 single detector isocratic or gravity chromatography stations several with auto-injectors and auto fraction collectors.
###end p 28
###begin title 29
Crystallization and structure determination
###end title 29
###begin p 30
###xml 742 749 742 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 742 749 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
High throughput crystallization methods and trials are being developed at UCSF. James Holton (UCSF and the Advanced Light Source (ALS) in Berkeley) is addressing bottlenecks in X-ray data collection and data analysis for 3D structure determination. Henning Stahlberg, UCDavis, is developing methods for streamlining EM structure determination, including automation of data collection and sample preparation. Electron crystallography is also being used to validate that the structures of 3-D crystalline samples are congruent with those in the 2D bilayer. Some membrane proteins may evade both structure determination schemes. NMR will be applied in these cases by Roland Riek for small size targets in addition to its own set of targets from E. coli.
###end p 30
###begin title 31
MISTIC homologs (Senyon Choe, Salk)
###end title 31
###begin p 32
###xml 480 488 480 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bacillus</italic>
###xml 599 607 599 607 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bacillus</italic>
###xml 679 686 679 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 1292 1303 1292 1303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B. subtilis</italic>
###xml 679 686 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 1292 1303 <span type="species:ncbi:1423">B. subtilis</span>
Mistic-based over-expression of bacterial kinase receptors has provided a significant advantage of over-producing this class of target proteins over other methods. But for mammalian integral membrane protein targets, it still needs significant optimization. Apart from using Mistic for protein expression, we have also made efforts to understand the function of the Mistic protein in the Bacillus organism. We have focused on the role by up-regulating the expression of Mistic in Bacillus. It led to a surprising consequence. It promotes the formation of biofilm and endows antibiotic resistance in Bacillus. To some extent, the same physiological results can be reproduced when E. coli is transfected and up-regulated by Mistic expression. Several Mistic homologs have been studied for their structures. One such homolog we termed M2 behaves well, and a 3.5 A dataset has been obtained from M2 crystals. The structure solution has not yet been obtained. Another such homolog we termed M1 behaves well in solution, for which high-quality NMR spectra have been obtained. Near complete assignment of M1 spectral peaks has been accomplished. These homologues have 62-93% residue identity, and are all 84 residues in length, corresponding to the three helices minus the first N-terminal helix of B. subtilis Mistic. In every case, these Mistic homologs have an overlapping gene read-out with a downstream gene that resembles a potassium channel protein. The functional relationship between the two genes is unknown.
###end p 32
###begin p 33
###xml 519 524 <span type="species:ncbi:9606">human</span>
Mistic technology has a limited use for eukaryotic targets. In order to explore the possible use of Mistic for eukaryotic targets, we have initiated using Mistic in lieu of a signal sequence present at the N-terminus of typical eukaryotic membrane protein genes. Initial expression constructs have been designed and will be compared to a comparable designer vector containing only the first alpha helical domain in place of the entire Mistic sequence. Once the designed vectors are available for tests, we will use the human integral membrane protein library that consists of ~3,270 target genes that have been constructed as a Gateway-adapted entry vectors.
###end p 33
###begin title 34
In vitro expression (Robert Stroud)
###end title 34
###begin p 35
###xml 254 261 254 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 312 319 312 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 342 349 342 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 254 261 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 312 319 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 342 349 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Reconstituted cell-free (CF) protein expression systems hold the promise of overcoming several of the traditional barriers associated with in vivo systems. To evaluate the potential of cell-free expression, we cloned 120 membrane (<30 kDa) proteins from E. coli and compared their expression profiles in both an E. coli in vivo system and an E. coli derived cell-free system. Our results indicated that cell-free was a robust system able to express 63% of the targets compared to 44% in vivo (reported in Yr. 2). However, when evaluating an expression system, many factors, such as cost, complexity, throughput, reaction efficiency and duration, personnel time, and protein quality, must be taken into account. While cell-free is a robust expression system capable of expressing more proteins than an in vivo system and suitable for production of membrane proteins at the milligram level for a relatively small cost when producing the S30 fraction in house; the in vivo system is more streamlined, able to be scaled up much easier with our equipment, and more economical in all cases where expression is successful. We are investigating the addition of lipids and/or detergents into the cell-free reaction mixtures to investigate the potential to increase expression and perhaps address the reaction duration issues. If we select a high value target that is not amenable to in vivo expression systems, we will try the cell free approach, but even if the expression level in vivo is quite low (<0.1 mg/l), our Sartorius fermentor units (2 x 15 l and 1 x 75 l) can usually provide enough protein to perform useful experiments.
###end p 35
###begin p 36
In year 3, we tested all of the phase 1 constructs that were positive for in vivo expression in larger growth volumes and prepared them for insertion into our regular in vivo expression, purification, and crystallization pathway.
###end p 36
###begin title 37
Gene redesign and codon optimization (Robert Stroud UCSF)
###end title 37
###begin p 38
Expression of functional protein targets in heterologous hosts is a key element of our efforts within the center. Utilization of codon optimized synthetic genes has been demonstrated in hundreds of published cases to increase, often significantly, the levels of expressed material for soluble proteins. Our efforts in CSMP focus on attempts to translate this observation to expression of integral membrane proteins. Within the past year we have generated codon-optimized genes for 21 different proteins that have lead to seven targets now in crystallization trials. Of these, three have crystallized (Tacid1, SecY and PfAQP) and have been optimized. Codon optimization for each of these proteins was essential for expression success and moving forward to crystallization trials. For instance, the native PfAQP protein did not express, likely owing to the AT rich character of the Plasmodium genome. Following optimization we are now obtaining ~42 g of purified protein/liter of culture. As evident from our initial expression results, we generally observe an improvement in protein expression levels. PfAQP has now had its structure determined to 2.05 A (PDB: 3C02).
###end p 38
###begin p 39
###xml 386 387 386 387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 389 396 389 396 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 396 442 396 442 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="40">Progress table for the codon usage experiments</p>
###xml 396 442 396 442 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="40">Progress table for the codon usage experiments</p></caption>
###xml 442 446 442 446 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Gene</th>
###xml 446 453 446 453 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Species</th>
###xml 453 459 453 459 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Design</th>
###xml 459 467 459 467 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Opt. For</th>
###xml 467 473 467 473 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Status</th>
###xml 473 489 473 489 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Native attempted</th>
###xml 489 500 489 500 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Improvement</th>
###xml 442 500 442 500 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Gene</th><th align="left">Species</th><th align="left">Design</th><th align="left">Opt. For</th><th align="left">Status</th><th align="left">Native attempted</th><th align="left">Improvement</th></tr>
###xml 442 500 442 500 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Gene</th><th align="left">Species</th><th align="left">Design</th><th align="left">Opt. For</th><th align="left">Status</th><th align="left">Native attempted</th><th align="left">Improvement</th></tr></thead>
###xml 500 506 500 506 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tacid1</td>
###xml 506 525 506 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Thermus acidophilus</italic>
###xml 506 525 506 525 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Thermus acidophilus</italic></td>
###xml 525 531 525 531 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">DNA2.0</td>
###xml 531 537 531 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. cer</italic>
###xml 531 537 531 537 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>S. cer</italic></td>
###xml 537 545 537 545 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Crystals</td>
###xml 545 548 545 548 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 548 552 548 552 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~10&#215;</td>
###xml 500 552 500 552 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Tacid1</td><td align="left"><italic>Thermus acidophilus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>S. cer</italic></td><td align="left">Crystals</td><td align="left">Yes</td><td align="left">~10&#215;</td></tr>
###xml 552 557 552 557 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PfAQP</td>
###xml 557 570 557 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. falciparum</italic>
###xml 557 570 557 570 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P. falciparum</italic></td>
###xml 570 575 570 575 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Kosan</td>
###xml 575 582 575 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 575 582 575 582 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>E. coli</italic></td>
###xml 582 590 582 590 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PDB 3CO2</td>
###xml 590 593 590 593 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 593 597 593 597 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~10&#215;</td>
###xml 552 597 552 597 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">PfAQP</td><td align="left"><italic>P. falciparum</italic></td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">PDB 3CO2</td><td align="left">Yes</td><td align="left">~10&#215;</td></tr>
###xml 597 601 597 601 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SecY</td>
###xml 601 620 601 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pyrococcus furiosus</italic>
###xml 601 620 601 620 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Pyrococcus furiosus</italic></td>
###xml 620 625 620 625 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Kosan</td>
###xml 625 632 625 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. fur.</italic>
###xml 625 632 625 632 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>P. fur.</italic></td>
###xml 632 640 632 640 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Crystals</td>
###xml 640 643 640 643 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 643 657 643 657 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~4&#215;, essential</td>
###xml 597 657 597 657 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">SecY</td><td align="left"><italic>Pyrococcus furiosus</italic></td><td align="left">Kosan</td><td align="left"><italic>P. fur.</italic></td><td align="left">Crystals</td><td align="left">Yes</td><td align="left">~4&#215;, essential</td></tr>
###xml 657 663 657 663 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HPV-2B</td>
###xml 663 666 663 666 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HPV</td>
###xml 666 671 666 671 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Kosan</td>
###xml 671 678 671 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 671 678 671 678 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>E. coli</italic></td>
###xml 678 692 678 692 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Crystal trials</td>
###xml 692 694 692 694 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 694 695 694 695 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 657 695 657 695 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HPV-2B</td><td align="left">HPV</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">No</td><td align="left">&#8211;</td></tr>
###xml 695 701 695 701 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HPV-3A</td>
###xml 701 704 701 704 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HPV</td>
###xml 704 709 704 709 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Kosan</td>
###xml 709 716 709 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 709 716 709 716 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>E. coli</italic></td>
###xml 716 730 716 730 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Crystal trials</td>
###xml 730 732 730 732 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 732 733 732 733 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 695 733 695 733 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HPV-3A</td><td align="left">HPV</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">No</td><td align="left">&#8211;</td></tr>
###xml 733 740 733 740 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rGamma2</td>
###xml 740 757 740 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus</italic>
###xml 740 757 740 757 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Rattus norvegicus</italic></td>
###xml 757 763 757 763 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">DNA2.0</td>
###xml 763 770 763 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 763 770 763 770 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>E. coli</italic></td>
###xml 770 784 770 784 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Crystal trials</td>
###xml 784 787 784 787 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 787 790 787 790 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~3&#215;</td>
###xml 733 790 733 790 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rGamma2</td><td align="left"><italic>Rattus norvegicus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">Yes</td><td align="left">~3&#215;</td></tr>
###xml 790 797 790 797 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rGamma5</td>
###xml 797 814 797 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Rattus norvegicus</italic>
###xml 797 814 797 814 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Rattus norvegicus</italic></td>
###xml 814 820 814 820 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">DNA2.0</td>
###xml 820 827 820 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 820 827 820 827 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>E. coli</italic></td>
###xml 827 841 827 841 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Crystal trials</td>
###xml 841 844 841 844 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 844 847 844 847 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~3&#215;</td>
###xml 790 847 790 847 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rGamma5</td><td align="left"><italic>Rattus norvegicus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">Yes</td><td align="left">~3&#215;</td></tr>
###xml 847 853 847 853 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tacid2</td>
###xml 853 867 853 867 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T. acidophilus</italic>
###xml 853 867 853 867 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>T. acidophilus</italic></td>
###xml 867 873 867 873 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">DNA2.0</td>
###xml 873 879 873 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. cer</italic>
###xml 873 879 873 879 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>S. cer</italic></td>
###xml 879 891 879 891 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Purification</td>
###xml 891 894 891 894 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 894 898 894 898 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~10&#215;</td>
###xml 847 898 847 898 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Tacid2</td><td align="left"><italic>T. acidophilus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>S. cer</italic></td><td align="left">Purification</td><td align="left">Yes</td><td align="left">~10&#215;</td></tr>
###xml 898 903 898 903 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Afmdr</td>
###xml 903 925 903 925 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Archaeoglobus fulgidus</italic>
###xml 903 925 903 925 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>Archaeoglobus fulgidus</italic></td>
###xml 925 931 925 931 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">DNA2.0</td>
###xml 931 938 931 938 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 931 938 931 938 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>E. coli</italic></td>
###xml 938 950 938 950 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Purification</td>
###xml 950 953 950 953 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 953 956 953 956 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~2&#215;</td>
###xml 898 956 898 956 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Afmdr</td><td align="left"><italic>Archaeoglobus fulgidus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>E. coli</italic></td><td align="left">Purification</td><td align="left">Yes</td><td align="left">~2&#215;</td></tr>
###xml 956 962 956 962 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hABCB1</td>
###xml 962 967 962 967 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Human</td>
###xml 967 980 967 980 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Codon Devices</td>
###xml 980 986 980 986 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. cer</italic>
###xml 980 986 980 986 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>S. cer</italic></td>
###xml 986 1000 986 1000 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Solubilization</td>
###xml 1000 1003 1000 1003 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 1003 1006 1003 1006 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~3&#215;</td>
###xml 956 1006 956 1006 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">hABCB1</td><td align="left">Human</td><td align="left">Codon Devices</td><td align="left"><italic>S. cer</italic></td><td align="left">Solubilization</td><td align="left">Yes</td><td align="left">~3&#215;</td></tr>
###xml 1006 1013 1006 1009 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">h&#945;7</td>
###xml 1013 1018 1009 1014 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Human</td>
###xml 1018 1023 1014 1019 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Kosan</td>
###xml 1023 1030 1019 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 1023 1030 1019 1026 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>E. coli</italic></td>
###xml 1030 1044 1026 1040 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Solubilization</td>
###xml 1044 1046 1040 1042 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 1046 1047 1042 1043 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 1006 1047 1006 1043 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">h&#945;7</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr>
###xml 1047 1050 1043 1046 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">h3a</td>
###xml 1050 1055 1046 1051 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Human</td>
###xml 1055 1060 1051 1056 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Kosan</td>
###xml 1060 1067 1056 1063 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 1060 1067 1056 1063 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>E. coli</italic></td>
###xml 1067 1081 1063 1077 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Solubilization</td>
###xml 1081 1083 1077 1079 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 1083 1084 1079 1080 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 1047 1084 1043 1080 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">h3a</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr>
###xml 1084 1088 1080 1084 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hDAT</td>
###xml 1088 1093 1084 1089 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Human</td>
###xml 1093 1098 1089 1094 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Kosan</td>
###xml 1098 1105 1094 1101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 1098 1105 1094 1101 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>E. coli</italic></td>
###xml 1105 1119 1101 1115 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Solubilization</td>
###xml 1119 1121 1115 1117 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 1121 1122 1117 1118 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 1084 1122 1080 1118 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">hDAT</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr>
###xml 1122 1126 1118 1122 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hNET</td>
###xml 1126 1131 1122 1127 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Human</td>
###xml 1131 1136 1127 1132 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Kosan</td>
###xml 1136 1143 1132 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 1136 1143 1132 1139 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>E. coli</italic></td>
###xml 1143 1157 1139 1153 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Solubilization</td>
###xml 1157 1159 1153 1155 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 1159 1160 1155 1156 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 1122 1160 1118 1156 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">hNET</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr>
###xml 1160 1165 1156 1161 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hSERT</td>
###xml 1165 1170 1161 1166 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Human</td>
###xml 1170 1175 1166 1171 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Kosan</td>
###xml 1175 1182 1171 1178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 1175 1182 1171 1178 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>E. coli</italic></td>
###xml 1182 1196 1178 1192 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Solubilization</td>
###xml 1196 1198 1192 1194 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 1198 1199 1194 1195 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 1160 1199 1156 1195 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">hSERT</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr>
###xml 1199 1204 1195 1200 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">dSERT</td>
###xml 1204 1209 1200 1205 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Human</td>
###xml 1209 1214 1205 1210 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Kosan</td>
###xml 1214 1221 1210 1217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 1214 1221 1210 1217 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>E. coli</italic></td>
###xml 1221 1235 1217 1231 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Solubilization</td>
###xml 1235 1237 1231 1233 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 1237 1238 1233 1234 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">&#8211;</td>
###xml 1199 1238 1195 1234 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">dSERT</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr>
###xml 1238 1244 1234 1240 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hABCA1</td>
###xml 1244 1249 1240 1245 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Human</td>
###xml 1249 1262 1245 1258 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Codon Devices</td>
###xml 1262 1268 1258 1264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. cer</italic>
###xml 1262 1268 1258 1264 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>S. cer</italic></td>
###xml 1268 1278 1264 1274 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Expression</td>
###xml 1278 1281 1274 1277 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 1281 1307 1277 1303 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No, still blank on western</td>
###xml 1238 1307 1234 1303 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">hABCA1</td><td align="left">Human</td><td align="left">Codon Devices</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">Yes</td><td align="left">No, still blank on western</td></tr>
###xml 1307 1312 1303 1308 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hRhAG</td>
###xml 1312 1317 1308 1313 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Human</td>
###xml 1317 1324 1313 1320 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GENEART</td>
###xml 1324 1330 1320 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. cer</italic>
###xml 1324 1330 1320 1326 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>S. cer</italic></td>
###xml 1330 1340 1326 1336 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Expression</td>
###xml 1340 1351 1336 1347 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">In progress</td>
###xml 1351 1370 1347 1366 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No, slight decrease</td>
###xml 1307 1370 1303 1366 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">hRhAG</td><td align="left">Human</td><td align="left">GENEART</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">In progress</td><td align="left">No, slight decrease</td></tr>
###xml 1370 1375 1366 1371 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hRhBG</td>
###xml 1375 1380 1371 1376 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Human</td>
###xml 1380 1387 1376 1383 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GENEART</td>
###xml 1387 1393 1383 1389 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. cer</italic>
###xml 1387 1393 1383 1389 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>S. cer</italic></td>
###xml 1393 1403 1389 1399 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Expression</td>
###xml 1403 1414 1399 1410 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">In progress</td>
###xml 1414 1416 1410 1412 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 1370 1416 1366 1412 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">hRhBG</td><td align="left">Human</td><td align="left">GENEART</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">In progress</td><td align="left">No</td></tr>
###xml 1416 1421 1412 1417 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hRhCG</td>
###xml 1421 1426 1417 1422 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Human</td>
###xml 1426 1433 1422 1429 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">GENEART</td>
###xml 1433 1439 1429 1435 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. cer</italic>
###xml 1433 1439 1429 1435 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>S. cer</italic></td>
###xml 1439 1449 1435 1445 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Expression</td>
###xml 1449 1460 1445 1456 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">In progress</td>
###xml 1460 1486 1456 1482 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes, detectable on western</td>
###xml 1416 1486 1412 1482 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">hRhCG</td><td align="left">Human</td><td align="left">GENEART</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">In progress</td><td align="left">Yes, detectable on western</td></tr>
###xml 1486 1490 1482 1486 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">C5aR</td>
###xml 1490 1495 1486 1491 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Human</td>
###xml 1495 1500 1491 1496 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Kosan</td>
###xml 1500 1506 1496 1502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. cer</italic>
###xml 1500 1506 1496 1502 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>S. cer</italic></td>
###xml 1506 1516 1502 1512 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Expression</td>
###xml 1516 1519 1512 1515 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 1519 1545 1515 1541 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes, detectable on western</td>
###xml 1486 1545 1482 1541 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">C5aR</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">Yes</td><td align="left">Yes, detectable on western</td></tr>
###xml 500 1545 500 1541 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">Tacid1</td><td align="left"><italic>Thermus acidophilus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>S. cer</italic></td><td align="left">Crystals</td><td align="left">Yes</td><td align="left">~10&#215;</td></tr><tr><td align="left">PfAQP</td><td align="left"><italic>P. falciparum</italic></td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">PDB 3CO2</td><td align="left">Yes</td><td align="left">~10&#215;</td></tr><tr><td align="left">SecY</td><td align="left"><italic>Pyrococcus furiosus</italic></td><td align="left">Kosan</td><td align="left"><italic>P. fur.</italic></td><td align="left">Crystals</td><td align="left">Yes</td><td align="left">~4&#215;, essential</td></tr><tr><td align="left">HPV-2B</td><td align="left">HPV</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">HPV-3A</td><td align="left">HPV</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">rGamma2</td><td align="left"><italic>Rattus norvegicus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">Yes</td><td align="left">~3&#215;</td></tr><tr><td align="left">rGamma5</td><td align="left"><italic>Rattus norvegicus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">Yes</td><td align="left">~3&#215;</td></tr><tr><td align="left">Tacid2</td><td align="left"><italic>T. acidophilus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>S. cer</italic></td><td align="left">Purification</td><td align="left">Yes</td><td align="left">~10&#215;</td></tr><tr><td align="left">Afmdr</td><td align="left"><italic>Archaeoglobus fulgidus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>E. coli</italic></td><td align="left">Purification</td><td align="left">Yes</td><td align="left">~2&#215;</td></tr><tr><td align="left">hABCB1</td><td align="left">Human</td><td align="left">Codon Devices</td><td align="left"><italic>S. cer</italic></td><td align="left">Solubilization</td><td align="left">Yes</td><td align="left">~3&#215;</td></tr><tr><td align="left">h&#945;7</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">h3a</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">hDAT</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">hNET</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">hSERT</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">dSERT</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">hABCA1</td><td align="left">Human</td><td align="left">Codon Devices</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">Yes</td><td align="left">No, still blank on western</td></tr><tr><td align="left">hRhAG</td><td align="left">Human</td><td align="left">GENEART</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">In progress</td><td align="left">No, slight decrease</td></tr><tr><td align="left">hRhBG</td><td align="left">Human</td><td align="left">GENEART</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">In progress</td><td align="left">No</td></tr><tr><td align="left">hRhCG</td><td align="left">Human</td><td align="left">GENEART</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">In progress</td><td align="left">Yes, detectable on western</td></tr><tr><td align="left">C5aR</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">Yes</td><td align="left">Yes, detectable on western</td></tr></tbody>
###xml 442 1545 442 1541 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left">Species</th><th align="left">Design</th><th align="left">Opt. For</th><th align="left">Status</th><th align="left">Native attempted</th><th align="left">Improvement</th></tr></thead><tbody><tr><td align="left">Tacid1</td><td align="left"><italic>Thermus acidophilus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>S. cer</italic></td><td align="left">Crystals</td><td align="left">Yes</td><td align="left">~10&#215;</td></tr><tr><td align="left">PfAQP</td><td align="left"><italic>P. falciparum</italic></td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">PDB 3CO2</td><td align="left">Yes</td><td align="left">~10&#215;</td></tr><tr><td align="left">SecY</td><td align="left"><italic>Pyrococcus furiosus</italic></td><td align="left">Kosan</td><td align="left"><italic>P. fur.</italic></td><td align="left">Crystals</td><td align="left">Yes</td><td align="left">~4&#215;, essential</td></tr><tr><td align="left">HPV-2B</td><td align="left">HPV</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">HPV-3A</td><td align="left">HPV</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">rGamma2</td><td align="left"><italic>Rattus norvegicus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">Yes</td><td align="left">~3&#215;</td></tr><tr><td align="left">rGamma5</td><td align="left"><italic>Rattus norvegicus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">Yes</td><td align="left">~3&#215;</td></tr><tr><td align="left">Tacid2</td><td align="left"><italic>T. acidophilus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>S. cer</italic></td><td align="left">Purification</td><td align="left">Yes</td><td align="left">~10&#215;</td></tr><tr><td align="left">Afmdr</td><td align="left"><italic>Archaeoglobus fulgidus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>E. coli</italic></td><td align="left">Purification</td><td align="left">Yes</td><td align="left">~2&#215;</td></tr><tr><td align="left">hABCB1</td><td align="left">Human</td><td align="left">Codon Devices</td><td align="left"><italic>S. cer</italic></td><td align="left">Solubilization</td><td align="left">Yes</td><td align="left">~3&#215;</td></tr><tr><td align="left">h&#945;7</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">h3a</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">hDAT</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">hNET</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">hSERT</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">dSERT</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">hABCA1</td><td align="left">Human</td><td align="left">Codon Devices</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">Yes</td><td align="left">No, still blank on western</td></tr><tr><td align="left">hRhAG</td><td align="left">Human</td><td align="left">GENEART</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">In progress</td><td align="left">No, slight decrease</td></tr><tr><td align="left">hRhBG</td><td align="left">Human</td><td align="left">GENEART</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">In progress</td><td align="left">No</td></tr><tr><td align="left">hRhCG</td><td align="left">Human</td><td align="left">GENEART</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">In progress</td><td align="left">Yes, detectable on western</td></tr><tr><td align="left">C5aR</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">Yes</td><td align="left">Yes, detectable on western</td></tr></tbody></table>
###xml 389 1545 389 1541 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="40">Progress table for the codon usage experiments</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Gene</th><th align="left">Species</th><th align="left">Design</th><th align="left">Opt. For</th><th align="left">Status</th><th align="left">Native attempted</th><th align="left">Improvement</th></tr></thead><tbody><tr><td align="left">Tacid1</td><td align="left"><italic>Thermus acidophilus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>S. cer</italic></td><td align="left">Crystals</td><td align="left">Yes</td><td align="left">~10&#215;</td></tr><tr><td align="left">PfAQP</td><td align="left"><italic>P. falciparum</italic></td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">PDB 3CO2</td><td align="left">Yes</td><td align="left">~10&#215;</td></tr><tr><td align="left">SecY</td><td align="left"><italic>Pyrococcus furiosus</italic></td><td align="left">Kosan</td><td align="left"><italic>P. fur.</italic></td><td align="left">Crystals</td><td align="left">Yes</td><td align="left">~4&#215;, essential</td></tr><tr><td align="left">HPV-2B</td><td align="left">HPV</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">HPV-3A</td><td align="left">HPV</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">rGamma2</td><td align="left"><italic>Rattus norvegicus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">Yes</td><td align="left">~3&#215;</td></tr><tr><td align="left">rGamma5</td><td align="left"><italic>Rattus norvegicus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>E. coli</italic></td><td align="left">Crystal trials</td><td align="left">Yes</td><td align="left">~3&#215;</td></tr><tr><td align="left">Tacid2</td><td align="left"><italic>T. acidophilus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>S. cer</italic></td><td align="left">Purification</td><td align="left">Yes</td><td align="left">~10&#215;</td></tr><tr><td align="left">Afmdr</td><td align="left"><italic>Archaeoglobus fulgidus</italic></td><td align="left">DNA2.0</td><td align="left"><italic>E. coli</italic></td><td align="left">Purification</td><td align="left">Yes</td><td align="left">~2&#215;</td></tr><tr><td align="left">hABCB1</td><td align="left">Human</td><td align="left">Codon Devices</td><td align="left"><italic>S. cer</italic></td><td align="left">Solubilization</td><td align="left">Yes</td><td align="left">~3&#215;</td></tr><tr><td align="left">h&#945;7</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">h3a</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">hDAT</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">hNET</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">hSERT</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">dSERT</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>E. coli</italic></td><td align="left">Solubilization</td><td align="left">No</td><td align="left">&#8211;</td></tr><tr><td align="left">hABCA1</td><td align="left">Human</td><td align="left">Codon Devices</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">Yes</td><td align="left">No, still blank on western</td></tr><tr><td align="left">hRhAG</td><td align="left">Human</td><td align="left">GENEART</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">In progress</td><td align="left">No, slight decrease</td></tr><tr><td align="left">hRhBG</td><td align="left">Human</td><td align="left">GENEART</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">In progress</td><td align="left">No</td></tr><tr><td align="left">hRhCG</td><td align="left">Human</td><td align="left">GENEART</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">In progress</td><td align="left">Yes, detectable on western</td></tr><tr><td align="left">C5aR</td><td align="left">Human</td><td align="left">Kosan</td><td align="left"><italic>S. cer</italic></td><td align="left">Expression</td><td align="left">Yes</td><td align="left">Yes, detectable on western</td></tr></tbody></table></table-wrap>
The Stroud laboratory now has a collaboration with DNA2.0 Inc. to pursue a study of the efficacy of codon-optimized genes. Dr. Franklin Hays has provided DNA 2.0 with our hENT1 genes and with the collaboration of Dr. Claus Gustafsson at DNA2.0, DNA2.0 will produce 20-25 different codon-optimized genes for CSMP to expression test and prepare for eventual crystallization trials (Table 1).Table 1Progress table for the codon usage experimentsGeneSpeciesDesignOpt. ForStatusNative attemptedImprovementTacid1Thermus acidophilusDNA2.0S. cerCrystalsYes~10xPfAQPP. falciparumKosanE. coliPDB 3CO2Yes~10xSecYPyrococcus furiosusKosanP. fur.CrystalsYes~4x, essentialHPV-2BHPVKosanE. coliCrystal trialsNo-HPV-3AHPVKosanE. coliCrystal trialsNo-rGamma2Rattus norvegicusDNA2.0E. coliCrystal trialsYes~3xrGamma5Rattus norvegicusDNA2.0E. coliCrystal trialsYes~3xTacid2T. acidophilusDNA2.0S. cerPurificationYes~10xAfmdrArchaeoglobus fulgidusDNA2.0E. coliPurificationYes~2xhABCB1HumanCodon DevicesS. cerSolubilizationYes~3xhalpha7HumanKosanE. coliSolubilizationNo-h3aHumanKosanE. coliSolubilizationNo-hDATHumanKosanE. coliSolubilizationNo-hNETHumanKosanE. coliSolubilizationNo-hSERTHumanKosanE. coliSolubilizationNo-dSERTHumanKosanE. coliSolubilizationNo-hABCA1HumanCodon DevicesS. cerExpressionYesNo, still blank on westernhRhAGHumanGENEARTS. cerExpressionIn progressNo, slight decreasehRhBGHumanGENEARTS. cerExpressionIn progressNohRhCGHumanGENEARTS. cerExpressionIn progressYes, detectable on westernC5aRHumanKosanS. cerExpressionYesYes, detectable on western
###end p 39
###begin p 40
Progress table for the codon usage experiments
###end p 40
###begin title 41
LIC vectors (Daniel Minor, Robert Stroud)
###end title 41
###begin p 42
###xml 522 529 522 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 522 529 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 640 658 <span type="species:ncbi:12227">tobacco etch virus</span>
###xml 660 663 <span type="species:ncbi:12227?0.9375">TEV</span>
###xml 788 791 <span type="species:ncbi:12227?0.9375">TEV</span>
In order to facilitate the large amount of cloning and construct screening required for the efforts of the labs involved in this PSI center, the Stroud and Minor labs have developed a suite of expression vectors that implement Ligation Independent Cloning (LIC) strategies. This approach obviates the use of restriction enzymes for joining target protein DNA to the vector and the need for enzymatic ligation steps in clone preparation. The method is efficient and yields ~90-100% positive clones. We have constructed LIC E. coli vectors bearing two N-terminal affinity tags in series, His6 and maltose binding protein (MBP), followed by a tobacco etch virus (TEV) protease site (termed HMT). The His6- and MBP-tags allow for two orthogonal affinity steps to be used in purification. The TEV site permits specific cleavage of the tags following purification. LIC cassettes with different combinations of tags and utilizing the 3C (PreScission) protease have also been constructed and used primarily by the Stroud laboratory.
###end p 42
###begin p 43
###xml 122 129 122 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 122 129 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 211 214 <span type="species:ncbi:12227?0.9375">TEV</span>
Because CSMP focuses on the potential value of the MISTIC fusion protein as a tool for expression of membrane proteins in E. coli, we made LIC constructs (termed HMisT) bearing, in series, His6, MISTIC, and the TEV site. We have also generated HMT LIC and HMisT LIC vectors that have an N-terminal signal peptide for use on target proteins where the N-terminal domain is known to be extracellular (ssHMT and ssHMisT).
###end p 43
###begin title 44
Development of a rapid expression assay based on GFP for proper expression and membrane insertion (Daniel Minor)
###end title 44
###begin p 45
###xml 208 215 208 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 208 215 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
In an effort to facilitate the screening and evaluation of target proteins, we have developed an LIC expression vector that uses green fluorescent protein (GFP) to monitor target protein expression levels in E. coli directly. This vector bears an LIC site followed by GFP and a His8 affinity tag. The premise is that only proteins that are expressed and properly folded will give robust fluorescence signals, as it is known that inclusion body formation suppresses the formation of the GFP chromaphore. Our initial experiments confirmed that well-expressed proteins turn the cells visibly green.
###end p 45
###begin p 46
In the past year of effort we have used our GFP vector format to screen the expression of 314 membrane proteins from extremophilic organisms. We found that 67/314 (21%) of our extremeophile targets expressed as well or better than the benchmark proteins in the GFP assay. To investigate whether there was a correlation between GFP fluorescence values (FSUs) and the amount of protein produced in the membrane fraction, we took 36 targets (29 from the >60,000 FSU pool and seven from the <60,000 FSU pool) and subjected them to an expression optimization protocol. We evaluated expression levels for each construct (108 total) at three expression temperatures (18, 25, and 37degreesC). 17 of our targets, once optimized, express at >5 mg/l in the membrane fraction. Thus, the GFP screen appears to be a reliable way to identify targets that have good potential to express at high levels in the membrane. Based on our results, there is a 90% probability that a target with a fluorescence value >60,000 FSU can be expressed at 0.5 mg/l or better, levels that are sufficient for further characterization and crystallization trials.
###end p 46
###begin p 47
We pursued purification and characterization of 24 of the targets that expressed at 0.5 mg/l or better. We are actively pursuing purification optimization for each candidate as well as crystallization trials. Our plans for FY04 are to pursue crystallization and structure determination of our cohort of well-expressed extremeophile membrane proteins. Additionally, we plan to work with Dr. Greg Hura at ALS beamline 12.3.1 to collect Small Angle X-ray Scattering (SAXS) data on all well-behaved samples. Recent implementation of robotic sample handling on the 12.3.1 SAXS end station together with our cohort of well-expressed, readily purified targets provides an excellent opportunity to investigate the potential of a yet underutilized way to obtain medium resolution information (particularly regarding multimerization state) for membrane proteins. It is anticipated that such efforts will also aid in sample improvements for our efforts on structure determination by crystallization and X-ray diffraction methods.
###end p 47
###begin title 48
Protein expression core (Witek Kwiatkowski, Casey Johnson, Luis Esquivies, Christopher Dickson, Inno Maslennikov, SALK)
###end title 48
###begin p 49
###xml 1071 1072 1071 1072 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 1103 1104 1103 1104 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 1136 1137 1136 1137 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 1166 1167 1166 1167 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
We have standardized the steps of vector construction, detergent screening, mini-scale expression tests, and protein scale-up and subsequently trouble-shooting. Using these standardized protocols, we plan to process 4 vectors made per week, and 2 protein expression and scale-up per week, on average. Once the expression vectors are made and confirmed, mini-scale protein expression tests are performed. Experiments to determine the optimal detergent type, most effective solubilization time and detergent concentration will be performed and the data entered into CSMP Central Database. Once the detergent is selected from the screening and expression is confirmed, the expression vectors are tested for scale-up protein preparation. As a general guideline, we evaluate by testing detergent exchange and concentration by NMR, testing by HPLC sizing, ion exchange chromatography, testing oligomeric state of the protein in solution by Analytical Ultracentrifuge, choosing purification protocol, setting up crystallization screens. If necessary, we change detergent (decyl-d-maltopyranoside (DM), dodecyl-d-maltopyranoside (DDM), octyl l-d-glucopyranoside (OG), nonyl-d-glucopyranoside (NG) are the choices) and repeat. This is performed by the Protein Analysis Core. A typical target protein will take 7 working days to pass through the detergent screening with day one and two being used to solubilize membrane preparations prepared before-hand, days 3 and 7 to run the samples on size exclusion chromatography and run signature SDS-PAGE gels and western blots and change and test different buffer conditions. Most of this work is not particularly suited to automation except through the use of auto-injectors on the HPLC systems.
###end p 49
###begin title 50
Purification and characterization: high throughput characterization of membrane protein detergent complex (Kwiatkowski, SALK)
###end title 50
###begin p 51
The identification and characterization of integral membrane proteins (IMPs) require stable protein-detergent complexes (PDCs) to be formed. We used a combination of light scattering, refractive index measurement, mass spectroscopy, NMR spectroscopy, and ultracentrifugation to carefully characterize detergents and proteins and their relative compositions in the PDCs. This information was essential to evaluate oligomeric states of samples, and thus the feasibility of crystallization.
###end p 51
###begin p 52
We use 1D-NMR spectroscopy to quantitatively monitor detergent concentration during sample purification. These data provide a useful gauge of the detergent's extraction potential for a given protein, detergent exchange efficiency, and detergent concentration after final ultra-filtration. To assess the homogeneity and oligomeric state of PDCs we used HPLC in line with light scattering, UV and refractive index instruments or, alternatively, the sedimentation velocity measurement by analytical centrifugation. These methods provide us with the quantified detergent-to-protein ratio and the mass of the entire PDC, and thus with the precise PDC composition. They also allow us to assess the capability of detergent additives to influence these important parameters.
###end p 52
###begin title 53
Crystallization and structure determination: automation of crystallization trials (Robert Stroud)
###end title 53
###begin p 54
###xml 469 472 469 470 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#169;</sup>
In the process of 3D structure determination of biological macromolecules, crystallization constitutes one of the major bottlenecks. The scarcity of sample for crystal trials constitutes a limiting step in particular in the case of membrane proteins. At the CSMP, we have implemented a 'high-throughput' crystallization strategy that covers two aspects: Robotic screening and optimization of crystallization conditions. A nanoliter scale crystallization robot (Mosquito(c) from TTP LabTech) is used to perform crystallization trials in 96 well-format plates. It is designed to prepare drops in both hanging- or sitting-drop mode using the vapor diffusion method. Drop size can be reduced to 200 nl (100 nl + 100 nl) without loss of accuracy and efficiency. This robot is easy to use, and it is a positive displacement pipetting robot that uses disposable tips. It therefore eliminates the risk of cross-contamination, and it eliminates the need for cleaning the tips.
###end p 54
###begin p 55
This system is used for screening initial crystallization conditions and also for optimization using a set of additive screens. We keep approximately 20 commercial crystallization screens of 96 conditions on-hand giving researchers 1,920 unique crystallization conditions in addition to custom chemical components. Working with 100 nl of a protein solution and 100 nl of the crystallization screen requires <10 mul of protein solution instead of the 192 mul needed for manual drop setting methods (2 mul + 2 mul drops). This represents a 20x reduction in the protein needed for each screen and thus a 20x increase in the number of screens that we can perform with a given volume of protein preparation. This improvement in efficiency permits effective screening with proteins that express 20x less that before, putting our minimum useful expression level around 0.1 mg/l. This crystallization robot was purchased by CSMP, and is shared, (as are costs) by all members of CSMP, and also by the Macromolecular Structure Group (msg.ucsf.edu), the Gladstone Research Institute, and the QB3 Institute. About 20 different groups currently use this robot.
###end p 55
###begin title 56
Optimizing X-ray structure determination (James Holton, Robert Stroud, ALS/UCSF)
###end title 56
###begin p 57
Work continues on narrowing the large numerical gap between collected data sets and published structures. World wide, this gap is roughly 50 to 1, and our analysis of the problem has demonstrated that this gap is due to a lack of understanding of the data quality requirements of modern structure-solving algorithms. Clearly, it is always best to have high quality data, but optimizing throughput, efficiency and success rates requires that the minimum data quality requirements be known.
###end p 57
###begin p 58
Establishing these limits empirically would require collecting data sets from a wide range of proteins and systematically varying different parameters such as crystal size, mosaic spread, exposure time and others. This is a very large parameter space. To aid this search, a quantitative model of the diffraction experiment and all its various sources of error was constructed. This diffraction experiment simulator (MLFSOM) is now a mature system and has begun to produce exciting results. Nearly all important physical phenomena in the diffraction experiment, including radiation damage, spot shape, anomalous differences, diffuse scattering, shutter jitter and beam flicker are all modeled from first principles. The simulation is performed on an absolute scale, so once the correct real-world values of flux, crystal volume and other physical parameters are entered the simulated images are not only remarkably realistic, but on the same scale as measured diffraction patterns. The simulated images are output in the .SMV file format so they can then be processed with modern data-processing software. In this way, the effect of varying experimental parameters (such as exposure time in seconds or crystal size in microns) can be precisely correlated to data quality and the "threshold of solvability" established for each. The advantage of absolute scale is that the optimal parameters derived from the simulation have the same units as the optimal parameters for data collection. For example, it has been found that the read-out noise of a modern detector has almost no impact on the accuracy of anomalous difference measurements, which implies that MAD/SAD data sets can be divided over many more images than previously thought. This prediction was experimentally tested, and it was found that higher redundancy with the same total exposure actually improves overall data quality. This new data collection strategy is now strongly encouraged at ALS 8.3.1.
###end p 58
###begin p 59
###xml 358 359 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 927 928 927 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
In May 2007, the ADSC Q210 detector in ALS 8.3.1 was replaced with a new, larger, ADSC Q315r detector. The increased surface area and lower intrinsic noise have enabled larger unit cell work, improved signal-to-noise (longer detector distances) and a 10-fold increase in the allowable data redundancy over the old detector. It is now clear from our studies [1] and others that radiation damage is fundamentally unpredictable. We have shown that heavy atom sites decay exponentially with dose, and the decay constants are reproducible for a given sample type. We have established that the best strategy for MAD data collection is to begin with a complete data set of very short exposures (1 s or less) and then repeat the complete data set with 2x the exposure time, then 4x the exposure time and continue until the crystal shows signs of decay. This decay can either be evaluated by monitoring the XANES spectrum of the metal [1] or by visual inspection of the decaying diffraction pattern. If the sites are robust, then all the data sets can be merged together, and if the sites are found to decay rapidly, then the radiation induced phasing (RIP) technique can be applied between the first and last data sets. Thus the same set of data is applicable to several structure solution pathways.
###end p 59
###begin p 60
###xml 168 169 168 169 <underline xmlns:xlink="http://www.w3.org/1999/xlink">O</underline>
###xml 176 177 176 177 <underline xmlns:xlink="http://www.w3.org/1999/xlink">T</underline>
###xml 183 184 183 184 <underline xmlns:xlink="http://www.w3.org/1999/xlink">I</underline>
###xml 194 195 194 195 <underline xmlns:xlink="http://www.w3.org/1999/xlink">S</underline>
Of course, once the requirements of a crystal are known, one must find a crystal that meets them. Two novel screening technologies are in development at ALS 8.3.1: the Offline Target Indication System (OTIS) and the "plate goniometer". OTIS circumvents the crystal-centering problem by using optical microscope images of a hand-centered crystal to re-center it at a later time. This effectively enables unattended data collection, which is done late at night. Screening is then done during the daylight hours, when users are more alert. Delayed data collection has now become a popular feature for users with overnight shifts.
###end p 60
###begin p 61
The "plate goniometer" is an in situ screening system developed in collaboration with the SIBYLS beamline 12.3.1 and Fluidigm Corporation. It is now operational and screening crystals at a rate of one per minute. With this system, crystals can be probed in their growth chamber, which eliminates the caveats and the labor of harvesting, mounting and cryoprotecting each crystal, all important considerations in crystal optimization. We have recently begun applying this technology to novel structural projects, including a membrane protein from CSMP.
###end p 61
###begin title 62
Describe plans for FY04 research activities
###end title 62
###begin p 63
###xml 32 39 <span type="species:ncbi:9606">persons</span>
The initial goals and principal persons proposed continue along the lines of their initial goals. We need to make a more seamless transfer of membrane proteins to electron microscopic analysis, which is underutilized due to supply at present. As new proteins are now being produced the equation has evolved and demands this streamlined transfer of material to UC Davis.
###end p 63
###begin p 64
###xml 171 176 <span type="species:ncbi:9606">human</span>
Bioinformatic methods will be applied increasingly here to help in pinpointing structures of highest impact on the membrane proteome. Increased focus will be added to the human membrane protein genes being assembled in GATEWAY vectors by Dr. Choe. These will be expressed as MISTIC fusions at CSMP.
###end p 64
###begin p 65
We have set-up a multi-center crystallization method comparison with several PSI centers (Hauptman-Woodward Institute, Ismagilov Laboratory at the University of Chicago, and the Kenis Laboratory at the University of Illinois Champaign-Urbana, Fluidigm Corporation) that specialize in high throughput crystallization methods. We will be able to assess the success of each method via their results with a standardized protein preparation that we provide. CSMP is producing sufficient DjkA protein in a PHS state to provide all of these groups with enough protein to run a selected number of our favorite commercial crystallization screens.
###end p 65
###begin p 66
At the end of year 3, the Stroud laboratory has 735 prokaryotic membranes cloned, 240 proteins demonstrating significant expression, 85 that have been solubilized, 36 in membrane purification; 11 entered crystallization, 11 crystallized, 6 diffracted and have 3 structures. We can expect a dramatic ramp up as we enter more proteins into purification.
###end p 66
###begin p 67
All the CSMP centers combined have 1072 proteins listed on our website database CSMP Central. To date, 771 have been cloned, 564 have tested positive for useful expression, 62 have been solubilized, 38 were PHS, 13 produced crystals, 11 diffracted, and 11 structures were determined.
###end p 67
###begin title 68
Progress on production and structural determination of non-redundant proteins from classes of challenging proteins: introduction and background
###end title 68
###begin p 69
###xml 215 222 215 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 242 249 242 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 215 222 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 242 249 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 358 363 <span type="species:ncbi:9606">human</span>
###xml 405 410 <span type="species:ncbi:9606">human</span>
Many eukaryotic membrane protein families have close homologs in bacteria whose structures provide insight into the structures of eukaryotic family members. Therefore a major focus is to determine the structures of E. coli membrane proteins. E. coli however, does not contain representatives of many families found in mammals, hence the focus on archaea and human membrane proteins. The major subclass in human is those membrane proteins that are localized in functional form in the plasma membrane of the cell. These include many drug targets.
###end p 69
###begin title 70
Describe your plans and progress in selecting targets for production and structure determination and structural coverage at granularity consistent with the PSI-2 policies and appropriate for your class of challenging proteins
###end title 70
###begin title 71
Target selection
###end title 71
###begin p 72
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Objective</italic>
Objective: Develop a target selection strategy to sample a broad range of membrane proteins from set of selected prokaryotic and eukaryotic organisms.
###end p 72
###begin title 73
Targets of special interest
###end title 73
###begin p 74
###xml 26 33 26 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 149 156 149 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 202 203 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">/</italic>
###xml 340 341 340 341 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 26 33 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 149 156 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
(a) Extensive pipeline of E. coli and prokaryotic membrane proteome proteins (Stroud), (b) Membrane Protein Complexes from Prokaryotes (Stroud), (c) E. coli membrane proteins expressed from the in vitro/in vivo comparison (Stroud), (d) ABC and SLC transporters (Giacomini), (e) Bacterial receptor kinases (Choe), (f) Lactate symporter and H+/nucleobase-ascorbate symporter YgfO (Kaback), (g) Transporters and channels (Stroud). Ammonia channels, Mercury transporters, aquaporins (Stroud), and (h) extremeophile membrane proteins (Minor).
###end p 74
###begin title 75
Target selection (Andrej Sali, UCSF)
###end title 75
###begin p 76
###xml 163 176 159 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. cerevisiae</italic>
###xml 163 176 <span type="species:ncbi:4932">S. cerevisiae</span>
As part of the CSMP effort, we selected a set of target proteins for structural studies that maximizes coverage of integral alpha-helical membrane proteins in the S. cerevisiae while at the same time minimizing the number of sequences.
###end p 76
###begin p 77
###xml 99 104 <span type="species:ncbi:4932">yeast</span>
###xml 274 279 <span type="species:ncbi:4932">yeast</span>
We used our analysis to guide target selection for the structural genomics of membrane proteins in yeast, aiming for complete coverage of integral membrane proteins predicted to have three or more alpha helices. We found that complete profile-based sequence coverage of the yeast genome required 361 total targets of the 622 total.
###end p 77
###begin p 78
###xml 103 104 103 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 894 900 890 896 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 900 958 896 954 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="79">Bioinformatic flow chart for CSMP protein target selection</p>
###xml 900 958 896 954 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="79">Bioinformatic flow chart for CSMP protein target selection</p></caption>
###xml 958 958 954 954 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10969_2008_9058_Fig1_HTML" id="MO1"/>
###xml 894 958 890 954 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="79">Bioinformatic flow chart for CSMP protein target selection</p></caption><graphic position="anchor" xlink:href="10969_2008_9058_Fig1_HTML" id="MO1"/></fig>
The overall membrane protein annotation process consisted of the following five steps detailed in Fig. 1: Membrane protein annotation pipeline. First, we identified integral membrane protein families in the Pfam database of protein families. Second, we collected protein sequences encoded by a diverse set of 34 genomes of interest to CSMP and predicted alpha-helical transmembrane proteins. Third, we generated sequence profiles for the identified membrane proteins in each genome and annotated the sequences in each sequence profile with organism and protein family identifiers. Fourth, we enumerated membrane protein families in each genome and connected significantly related membrane proteins both within organisms and across organisms. Finally, we constructed comparative protein structure models for all known sequences from Uniprot based on known atomic structures of membrane proteins.Fig. 1Bioinformatic flow chart for CSMP protein target selection
###end p 78
###begin p 79
Bioinformatic flow chart for CSMP protein target selection
###end p 79
###begin p 80
###xml 48 53 <span type="species:ncbi:4932">yeast</span>
Complete profile-based sequence coverage of the yeast genome therefore requires 361 total targets of the 622 total. These sequences were added to the target selection tool and entered in to the experimental structural characterization pipeline in the Stroud group.
###end p 80
###begin p 81
One goal of structural genomics is to improve comparative modeling of sequence space. Finding homologs that can be modeled based on a template structure is the first step in the modeling process. We use our sequence profiles for each target sequence as a proxy for how many sequences could be modeled if we had a structure of the target. In total, there are 415,983 sequences in Uniprot that are detectably homologous to one or more of the CSMP targets. We find that our target selection methodology yields more unique modelable sequences and better profile-based sequence coverage than randomly selected sequences at 30% sequence identity.
###end p 81
###begin title 82
###xml 9 14 <span type="species:ncbi:9606">human</span>
###xml 51 56 <span type="species:ncbi:4932">yeast</span>
Focus on human ABC and SLC transporter homologs in yeast
###end title 82
###begin p 83
###xml 26 31 <span type="species:ncbi:4932">yeast</span>
###xml 103 108 <span type="species:ncbi:9606">human</span>
###xml 222 227 <span type="species:ncbi:9606">human</span>
Two selected targets, the yeast genes STE6 and YN_99, code for ABC transporters that are homologous to human multidrug transporters in the B and G families, respectively. There are 48 characterized ABC transporters in the human genome and 18 are disease-associated. Additional structural data these transporter families will be invaluable for interpreting the results of functional studies and suggesting mechanisms for clinical phenotypes.
###end p 83
###begin title 84
Expression of membrane proteins
###end title 84
###begin p 85
###xml 22 29 22 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 680 687 680 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 1082 1089 1082 1089 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 1168 1175 1168 1175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 22 29 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 680 687 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 1082 1089 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 1168 1175 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Extensive pipeline of E. coli and prokaryotic membrane proteome proteins (Robert Stroud). In the Stroud laboratory, we have a three phase organization to our work. First, we initially started on a 120 protein project investigating in vitro translation/expression. The results of this work were published in 2007 and the target proteins that expressed successfully moved into the purification pathway, this work is continuing. The second phase was our "408" protein project that was headed by Melissa Del Rosario. The proteins in this project were selected with the aid of the bioinformatics group in the Andrei Sali laboratory to provide extensive coverage of the Pfam classes in E. coli. Phase 2 has provided a large number of proteins that are ready for expression and solubility testing. From prior experience it was decided to test for solubility in octyl glucopyranoside (OG) detergent only. With this operational filter, we still had enough proteins that solubilized in OG to saturate our purification resources. In Phase three, since we had covered a significant part of the E. coli genome already in the first two phases, it was decided to complete the entire E. coli membrane protein proteome by selecting the remaining unselected proteins. All three phases are continuing presently.
###end p 85
###begin title 86
###xml 0 7 0 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 0 7 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
E. coli membrane proteins expressed from the in vitro/in vivo comparison (Robert Stroud)
###end title 86
###begin p 87
###xml 72 79 72 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 88 95 88 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 144 145 144 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 72 79 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 88 95 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Of the 120 proteins that were subject to expression testing in both the E. coli, and by E. coli cell-free methods, 12 of the membrane proteins [2] expressed at greater than one milligram per liter of culture and were able to be solubilized in OG and were therefore selected as targets for X-ray crystallography. Four have gone forward to crystal trials, and have been crystallized. CcmG and YijD crystals have gone to the ALS and diffract to 2.3 and 7.5 A, respectively. The structure of CcmG is currently being solved by molecular replacement (a structure of the soluble component of CcmG has been published, but not the transmembrane segment). Crystals of YijD are being further optimized with grid and additive screens.
###end p 87
###begin title 88
Protein production and structure determination (UCSF-Harries, Miercke, Stroud)
###end title 88
###begin title 89
Prokaryotic membrane proteins
###end title 89
###begin p 90
###xml 1419 1420 1419 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1510 1511 1510 1511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 1584 1585 1584 1585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 1595 1596 1595 1596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 1946 1953 1946 1953 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 1953 1997 1953 1997 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="91">STROUD prokaryotic membrane protein progress</p>
###xml 1953 1997 1953 1997 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="91">STROUD prokaryotic membrane protein progress</p></caption>
###xml 1997 2010 1997 2010 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Progress step</th>
###xml 2010 2026 2010 2026 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Step description</th>
###xml 2026 2038 2026 2038 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No. in group</th>
###xml 2038 2066 2038 2066 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Total no. through this level</th>
###xml 1997 2066 1997 2066 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Progress step</th><th align="left">Step description</th><th align="left">No. in group</th><th align="left">Total no. through this level</th></tr>
###xml 1997 2066 1997 2066 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Progress step</th><th align="left">Step description</th><th align="left">No. in group</th><th align="left">Total no. through this level</th></tr></thead>
###xml 2066 2068 2066 2068 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12</td>
###xml 2068 2077 2068 2077 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Structure</td>
###xml 2077 2078 2077 2078 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2078 2079 2078 2079 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">5</td>
###xml 2066 2079 2066 2079 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">12</td><td align="left">Structure</td><td char="." align="char">5</td><td char="." align="char">5</td></tr>
###xml 2079 2081 2079 2081 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">11</td>
###xml 2081 2092 2081 2092 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Diffraction</td>
###xml 2092 2093 2092 2093 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 2093 2094 2093 2094 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8</td>
###xml 2079 2094 2079 2094 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">11</td><td align="left">Diffraction</td><td char="." align="char">2</td><td char="." align="char">8</td></tr>
###xml 2094 2096 2094 2096 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">10</td>
###xml 2096 2104 2096 2104 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Crystals</td>
###xml 2104 2105 2104 2105 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 2105 2106 2105 2106 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8</td>
###xml 2094 2106 2094 2106 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">10</td><td align="left">Crystals</td><td char="." align="char">0</td><td char="." align="char">8</td></tr>
###xml 2106 2107 2106 2107 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9</td>
###xml 2107 2110 2107 2110 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PHS</td>
###xml 2110 2112 2110 2112 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25</td>
###xml 2112 2114 2112 2114 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">33</td>
###xml 2106 2114 2106 2114 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">9</td><td align="left">PHS</td><td char="." align="char">25</td><td char="." align="char">33</td></tr>
###xml 2114 2115 2114 2115 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8</td>
###xml 2115 2122 2115 2122 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">S-Chrom</td>
###xml 2122 2123 2122 2123 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 2123 2125 2123 2125 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">33</td>
###xml 2114 2125 2114 2125 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">8</td><td align="left">S-Chrom</td><td char="." align="char">0</td><td char="." align="char">33</td></tr>
###xml 2125 2126 2125 2126 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7</td>
###xml 2126 2133 2126 2133 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Q-Chrom</td>
###xml 2133 2134 2133 2134 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 2134 2136 2134 2136 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">33</td>
###xml 2125 2136 2125 2136 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">7</td><td align="left">Q-Chrom</td><td char="." align="char">0</td><td char="." align="char">33</td></tr>
###xml 2136 2137 2136 2137 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6</td>
###xml 2137 2148 2137 2148 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tag Cleaved</td>
###xml 2148 2149 2148 2149 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 2149 2151 2149 2151 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">33</td>
###xml 2136 2151 2136 2151 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">6</td><td align="left">Tag Cleaved</td><td char="." align="char">0</td><td char="." align="char">33</td></tr>
###xml 2151 2152 2151 2152 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5</td>
###xml 2152 2155 2152 2155 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SEC</td>
###xml 2155 2156 2155 2156 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 2156 2158 2156 2158 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">35</td>
###xml 2151 2158 2151 2158 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">5</td><td align="left">SEC</td><td char="." align="char">2</td><td char="." align="char">35</td></tr>
###xml 2158 2159 2158 2159 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4</td>
###xml 2159 2168 2159 2168 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Aff Chrom</td>
###xml 2168 2169 2168 2169 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 2169 2171 2169 2171 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">35</td>
###xml 2158 2171 2158 2171 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">4</td><td align="left">Aff Chrom</td><td char="." align="char">0</td><td char="." align="char">35</td></tr>
###xml 2171 2172 2171 2172 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 2172 2179 2172 2179 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Soluble</td>
###xml 2179 2181 2179 2181 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">22</td>
###xml 2181 2183 2181 2183 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">55</td>
###xml 2171 2183 2171 2183 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">3</td><td align="left">Soluble</td><td char="." align="char">22</td><td char="." align="char">55</td></tr>
###xml 2183 2184 2183 2184 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2</td>
###xml 2184 2199 2184 2199 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Significant exp</td>
###xml 2199 2202 2199 2202 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">240</td>
###xml 2202 2205 2202 2205 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">240</td>
###xml 2183 2205 2183 2205 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">2</td><td align="left">Significant exp</td><td char="." align="char">240</td><td char="." align="char">240</td></tr>
###xml 2205 2206 2205 2206 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 2206 2215 2206 2215 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Selection</td>
###xml 2215 2218 2215 2218 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">735</td>
###xml 2218 2221 2218 2221 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">735</td>
###xml 2205 2221 2205 2221 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">1</td><td align="left">Selection</td><td char="." align="char">735</td><td char="." align="char">735</td></tr>
###xml 2066 2221 2066 2221 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">12</td><td align="left">Structure</td><td char="." align="char">5</td><td char="." align="char">5</td></tr><tr><td align="left">11</td><td align="left">Diffraction</td><td char="." align="char">2</td><td char="." align="char">8</td></tr><tr><td align="left">10</td><td align="left">Crystals</td><td char="." align="char">0</td><td char="." align="char">8</td></tr><tr><td align="left">9</td><td align="left">PHS</td><td char="." align="char">25</td><td char="." align="char">33</td></tr><tr><td align="left">8</td><td align="left">S-Chrom</td><td char="." align="char">0</td><td char="." align="char">33</td></tr><tr><td align="left">7</td><td align="left">Q-Chrom</td><td char="." align="char">0</td><td char="." align="char">33</td></tr><tr><td align="left">6</td><td align="left">Tag Cleaved</td><td char="." align="char">0</td><td char="." align="char">33</td></tr><tr><td align="left">5</td><td align="left">SEC</td><td char="." align="char">2</td><td char="." align="char">35</td></tr><tr><td align="left">4</td><td align="left">Aff Chrom</td><td char="." align="char">0</td><td char="." align="char">35</td></tr><tr><td align="left">3</td><td align="left">Soluble</td><td char="." align="char">22</td><td char="." align="char">55</td></tr><tr><td align="left">2</td><td align="left">Significant exp</td><td char="." align="char">240</td><td char="." align="char">240</td></tr><tr><td align="left">1</td><td align="left">Selection</td><td char="." align="char">735</td><td char="." align="char">735</td></tr></tbody>
###xml 1997 2221 1997 2221 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Progress step</th><th align="left">Step description</th><th align="left">No. in group</th><th align="left">Total no. through this level</th></tr></thead><tbody><tr><td align="left">12</td><td align="left">Structure</td><td char="." align="char">5</td><td char="." align="char">5</td></tr><tr><td align="left">11</td><td align="left">Diffraction</td><td char="." align="char">2</td><td char="." align="char">8</td></tr><tr><td align="left">10</td><td align="left">Crystals</td><td char="." align="char">0</td><td char="." align="char">8</td></tr><tr><td align="left">9</td><td align="left">PHS</td><td char="." align="char">25</td><td char="." align="char">33</td></tr><tr><td align="left">8</td><td align="left">S-Chrom</td><td char="." align="char">0</td><td char="." align="char">33</td></tr><tr><td align="left">7</td><td align="left">Q-Chrom</td><td char="." align="char">0</td><td char="." align="char">33</td></tr><tr><td align="left">6</td><td align="left">Tag Cleaved</td><td char="." align="char">0</td><td char="." align="char">33</td></tr><tr><td align="left">5</td><td align="left">SEC</td><td char="." align="char">2</td><td char="." align="char">35</td></tr><tr><td align="left">4</td><td align="left">Aff Chrom</td><td char="." align="char">0</td><td char="." align="char">35</td></tr><tr><td align="left">3</td><td align="left">Soluble</td><td char="." align="char">22</td><td char="." align="char">55</td></tr><tr><td align="left">2</td><td align="left">Significant exp</td><td char="." align="char">240</td><td char="." align="char">240</td></tr><tr><td align="left">1</td><td align="left">Selection</td><td char="." align="char">735</td><td char="." align="char">735</td></tr></tbody></table>
###xml 1946 2221 1946 2221 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="91">STROUD prokaryotic membrane protein progress</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Progress step</th><th align="left">Step description</th><th align="left">No. in group</th><th align="left">Total no. through this level</th></tr></thead><tbody><tr><td align="left">12</td><td align="left">Structure</td><td char="." align="char">5</td><td char="." align="char">5</td></tr><tr><td align="left">11</td><td align="left">Diffraction</td><td char="." align="char">2</td><td char="." align="char">8</td></tr><tr><td align="left">10</td><td align="left">Crystals</td><td char="." align="char">0</td><td char="." align="char">8</td></tr><tr><td align="left">9</td><td align="left">PHS</td><td char="." align="char">25</td><td char="." align="char">33</td></tr><tr><td align="left">8</td><td align="left">S-Chrom</td><td char="." align="char">0</td><td char="." align="char">33</td></tr><tr><td align="left">7</td><td align="left">Q-Chrom</td><td char="." align="char">0</td><td char="." align="char">33</td></tr><tr><td align="left">6</td><td align="left">Tag Cleaved</td><td char="." align="char">0</td><td char="." align="char">33</td></tr><tr><td align="left">5</td><td align="left">SEC</td><td char="." align="char">2</td><td char="." align="char">35</td></tr><tr><td align="left">4</td><td align="left">Aff Chrom</td><td char="." align="char">0</td><td char="." align="char">35</td></tr><tr><td align="left">3</td><td align="left">Soluble</td><td char="." align="char">22</td><td char="." align="char">55</td></tr><tr><td align="left">2</td><td align="left">Significant exp</td><td char="." align="char">240</td><td char="." align="char">240</td></tr><tr><td align="left">1</td><td align="left">Selection</td><td char="." align="char">735</td><td char="." align="char">735</td></tr></tbody></table></table-wrap>
We currently have 735 prokaryotic membrane proteins in our protein purification pipeline. So far, 155 proteins express at levels high enough to proceed to solubility testing using a detergent screen with six different detergents representing three detergent chemical families. 85 of the solubilized proteins have been successfully purified on Ni IMAC. Once the Ni immobilized metal affinity chromatography (IMAC) purification efficiency has been assured by SDS-PAGE and western blots, the histidine tags are cleaved for preparative SEC runs. If the SEC produces a pure homogenous single peak, the sample is tested for stability; at this time, 34 of the post-SEC proteins are pure, homogenous, and stable (PHS). If a protein preparation can not be adequately purified by SEC, ion-exchange chromatography using methyl sulphonate (S) or quaternary ammonium (Q) matrices are used for further purification. Size exclusion chromatography is routinely employed to test the PHS condition of all preparations. Once a protein preparation is PHS it is ready for crystal trials. At the end of year 3, the Stroud laboratory has 735 prokaryotic membranes cloned, 240 proteins demonstrating significant expression, 55 that have been solubilized, 36 in membrane purification; 11 entered crystallization, 11 crystallized, six diffracted and have four structures. One structure is of a primitive Rh factor from Nitrosomonas (PDB: 3bhs, [3]), two are published structures of AQPM solved at 1.67 A and 2.3 A (PDB: 2evu and 2f2b, [4]), and the other is an AmtB-GlnK complex refined to 1.95 A (PDB: 2ns1, [3]) (Table 2). We can expect a dramatic ramp up as we enter more proteins into purification. However, the bottleneck for us is protein purification. We therefore seek to augment the effort there with increased efficiency, additional chromatography stations, and possibly additional personnel if we can appropriately refocus less productive prototype experiments.Table 2STROUD prokaryotic membrane protein progressProgress stepStep descriptionNo. in groupTotal no. through this level12Structure5511Diffraction2810Crystals089PHS25338S-Chrom0337Q-Chrom0336Tag Cleaved0335SEC2354Aff Chrom0353Soluble22552Significant exp2402401Selection735735
###end p 90
###begin p 91
STROUD prokaryotic membrane protein progress
###end p 91
###begin p 92
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 293 300 293 300 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 300 330 300 330 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="93">CSMP membrane protein progress</p>
###xml 300 330 300 330 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="93">CSMP membrane protein progress</p></caption>
###xml 330 343 330 343 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Progress step</th>
###xml 343 359 343 359 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Step description</th>
###xml 359 371 359 371 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No. in group</th>
###xml 371 399 371 399 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Total no. through this level</th>
###xml 330 399 330 399 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Progress step</th><th align="left">Step description</th><th align="left">No. in group</th><th align="left">Total no. through this level</th></tr>
###xml 330 399 330 399 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Progress step</th><th align="left">Step description</th><th align="left">No. in group</th><th align="left">Total no. through this level</th></tr></thead>
###xml 399 401 399 401 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12</td>
###xml 401 410 401 410 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Structure</td>
###xml 410 412 410 412 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 412 414 412 414 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 399 414 399 414 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">12</td><td align="left">Structure</td><td char="." align="char">11</td><td char="." align="char">11</td></tr>
###xml 414 416 414 416 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">11</td>
###xml 416 427 416 427 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Diffraction</td>
###xml 427 429 427 429 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 429 431 429 431 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 414 431 414 431 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">11</td><td align="left">Diffraction</td><td char="." align="char">11</td><td char="." align="char">11</td></tr>
###xml 431 433 431 433 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">10</td>
###xml 433 441 433 441 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Crystals</td>
###xml 441 442 441 442 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 442 444 442 444 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">13</td>
###xml 431 444 431 444 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">10</td><td align="left">Crystals</td><td char="." align="char">2</td><td char="." align="char">13</td></tr>
###xml 444 445 444 445 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9</td>
###xml 445 448 445 448 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">PHS</td>
###xml 448 450 448 450 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25</td>
###xml 450 452 450 452 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38</td>
###xml 444 452 444 452 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">9</td><td align="left">PHS</td><td char="." align="char">25</td><td char="." align="char">38</td></tr>
###xml 452 453 452 453 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8</td>
###xml 453 460 453 460 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">S-Chrom</td>
###xml 460 461 460 461 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 461 463 461 463 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38</td>
###xml 452 463 452 463 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">8</td><td align="left">S-Chrom</td><td char="." align="char">0</td><td char="." align="char">38</td></tr>
###xml 463 464 463 464 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7</td>
###xml 464 471 464 471 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Q-Chrom</td>
###xml 471 472 471 472 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 472 474 472 474 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38</td>
###xml 463 474 463 474 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">7</td><td align="left">Q-Chrom</td><td char="." align="char">0</td><td char="." align="char">38</td></tr>
###xml 474 475 474 475 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6</td>
###xml 475 486 475 486 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Tag Cleaved</td>
###xml 486 487 486 487 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 487 489 487 489 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">38</td>
###xml 474 489 474 489 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">6</td><td align="left">Tag Cleaved</td><td char="." align="char">0</td><td char="." align="char">38</td></tr>
###xml 489 490 489 490 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5</td>
###xml 490 493 490 493 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">SEC</td>
###xml 493 494 493 494 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">2</td>
###xml 494 496 494 496 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">40</td>
###xml 489 496 489 496 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">5</td><td align="left">SEC</td><td char="." align="char">2</td><td char="." align="char">40</td></tr>
###xml 496 497 496 497 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4</td>
###xml 497 506 497 506 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Aff Chrom</td>
###xml 506 507 506 507 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 507 509 507 509 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">40</td>
###xml 496 509 496 509 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">4</td><td align="left">Aff Chrom</td><td char="." align="char">0</td><td char="." align="char">40</td></tr>
###xml 509 510 509 510 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 510 517 510 517 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Soluble</td>
###xml 517 519 517 519 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">22</td>
###xml 519 521 519 521 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">62</td>
###xml 509 521 509 521 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">3</td><td align="left">Soluble</td><td char="." align="char">22</td><td char="." align="char">62</td></tr>
###xml 521 522 521 522 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2</td>
###xml 522 533 522 533 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Initial exp</td>
###xml 533 536 533 536 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">628</td>
###xml 536 539 536 539 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">628</td>
###xml 521 539 521 539 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">2</td><td align="left">Initial exp</td><td char="." align="char">628</td><td char="." align="char">628</td></tr>
###xml 539 540 539 540 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 540 549 540 549 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Selection</td>
###xml 549 553 549 553 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1072</td>
###xml 553 557 553 557 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1072</td>
###xml 539 557 539 557 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">1</td><td align="left">Selection</td><td char="." align="char">1072</td><td char="." align="char">1072</td></tr>
###xml 399 557 399 557 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">12</td><td align="left">Structure</td><td char="." align="char">11</td><td char="." align="char">11</td></tr><tr><td align="left">11</td><td align="left">Diffraction</td><td char="." align="char">11</td><td char="." align="char">11</td></tr><tr><td align="left">10</td><td align="left">Crystals</td><td char="." align="char">2</td><td char="." align="char">13</td></tr><tr><td align="left">9</td><td align="left">PHS</td><td char="." align="char">25</td><td char="." align="char">38</td></tr><tr><td align="left">8</td><td align="left">S-Chrom</td><td char="." align="char">0</td><td char="." align="char">38</td></tr><tr><td align="left">7</td><td align="left">Q-Chrom</td><td char="." align="char">0</td><td char="." align="char">38</td></tr><tr><td align="left">6</td><td align="left">Tag Cleaved</td><td char="." align="char">0</td><td char="." align="char">38</td></tr><tr><td align="left">5</td><td align="left">SEC</td><td char="." align="char">2</td><td char="." align="char">40</td></tr><tr><td align="left">4</td><td align="left">Aff Chrom</td><td char="." align="char">0</td><td char="." align="char">40</td></tr><tr><td align="left">3</td><td align="left">Soluble</td><td char="." align="char">22</td><td char="." align="char">62</td></tr><tr><td align="left">2</td><td align="left">Initial exp</td><td char="." align="char">628</td><td char="." align="char">628</td></tr><tr><td align="left">1</td><td align="left">Selection</td><td char="." align="char">1072</td><td char="." align="char">1072</td></tr></tbody>
###xml 330 557 330 557 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Progress step</th><th align="left">Step description</th><th align="left">No. in group</th><th align="left">Total no. through this level</th></tr></thead><tbody><tr><td align="left">12</td><td align="left">Structure</td><td char="." align="char">11</td><td char="." align="char">11</td></tr><tr><td align="left">11</td><td align="left">Diffraction</td><td char="." align="char">11</td><td char="." align="char">11</td></tr><tr><td align="left">10</td><td align="left">Crystals</td><td char="." align="char">2</td><td char="." align="char">13</td></tr><tr><td align="left">9</td><td align="left">PHS</td><td char="." align="char">25</td><td char="." align="char">38</td></tr><tr><td align="left">8</td><td align="left">S-Chrom</td><td char="." align="char">0</td><td char="." align="char">38</td></tr><tr><td align="left">7</td><td align="left">Q-Chrom</td><td char="." align="char">0</td><td char="." align="char">38</td></tr><tr><td align="left">6</td><td align="left">Tag Cleaved</td><td char="." align="char">0</td><td char="." align="char">38</td></tr><tr><td align="left">5</td><td align="left">SEC</td><td char="." align="char">2</td><td char="." align="char">40</td></tr><tr><td align="left">4</td><td align="left">Aff Chrom</td><td char="." align="char">0</td><td char="." align="char">40</td></tr><tr><td align="left">3</td><td align="left">Soluble</td><td char="." align="char">22</td><td char="." align="char">62</td></tr><tr><td align="left">2</td><td align="left">Initial exp</td><td char="." align="char">628</td><td char="." align="char">628</td></tr><tr><td align="left">1</td><td align="left">Selection</td><td char="." align="char">1072</td><td char="." align="char">1072</td></tr></tbody></table>
###xml 293 557 293 557 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="93">CSMP membrane protein progress</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Progress step</th><th align="left">Step description</th><th align="left">No. in group</th><th align="left">Total no. through this level</th></tr></thead><tbody><tr><td align="left">12</td><td align="left">Structure</td><td char="." align="char">11</td><td char="." align="char">11</td></tr><tr><td align="left">11</td><td align="left">Diffraction</td><td char="." align="char">11</td><td char="." align="char">11</td></tr><tr><td align="left">10</td><td align="left">Crystals</td><td char="." align="char">2</td><td char="." align="char">13</td></tr><tr><td align="left">9</td><td align="left">PHS</td><td char="." align="char">25</td><td char="." align="char">38</td></tr><tr><td align="left">8</td><td align="left">S-Chrom</td><td char="." align="char">0</td><td char="." align="char">38</td></tr><tr><td align="left">7</td><td align="left">Q-Chrom</td><td char="." align="char">0</td><td char="." align="char">38</td></tr><tr><td align="left">6</td><td align="left">Tag Cleaved</td><td char="." align="char">0</td><td char="." align="char">38</td></tr><tr><td align="left">5</td><td align="left">SEC</td><td char="." align="char">2</td><td char="." align="char">40</td></tr><tr><td align="left">4</td><td align="left">Aff Chrom</td><td char="." align="char">0</td><td char="." align="char">40</td></tr><tr><td align="left">3</td><td align="left">Soluble</td><td char="." align="char">22</td><td char="." align="char">62</td></tr><tr><td align="left">2</td><td align="left">Initial exp</td><td char="." align="char">628</td><td char="." align="char">628</td></tr><tr><td align="left">1</td><td align="left">Selection</td><td char="." align="char">1072</td><td char="." align="char">1072</td></tr></tbody></table></table-wrap>
All the CSMP centers combined have 1072 proteins listed on our website database CSMP Central. To date, 771 have been cloned, 564 have tested positive for useful expression, 62 have been solubilized, 38 were PHS, 13 produced crystals, 11 diffracted, and 11 structures were determined (Table 3).Table 3CSMP membrane protein progressProgress stepStep descriptionNo. in groupTotal no. through this level12Structure111111Diffraction111110Crystals2139PHS25388S-Chrom0387Q-Chrom0386Tag Cleaved0385SEC2404Aff Chrom0403Soluble22622Initial exp6286281Selection10721072
###end p 92
###begin p 93
CSMP membrane protein progress
###end p 93
###begin title 94
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human membrane proteins
###end title 94
###begin p 95
###xml 11 16 <span type="species:ncbi:9606">human</span>
###xml 332 337 <span type="species:ncbi:9606">human</span>
Thirty-six human membrane protein targets have entered the Protein Expression and Production Pipeline. Ten of these express adequately to continue through the pipeline. So far, nine of these have been solubilized and moved on to the purification process. Purification protocols for all 9 are in the process of being fine-tuned. One human protein has been crystallized.
###end p 95
###begin title 96
Membrane protein complexes from prokaryotes (Robert Stroud)
###end title 96
###begin p 97
###xml 312 332 312 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Acinetobacter baylyi</italic>
###xml 339 355 339 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Escherichia coli</italic>
###xml 361 387 361 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mycobacterium tuberculosis</italic>
###xml 399 421 399 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudomonas aeruginosa</italic>
###xml 522 529 522 529 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 312 332 <span type="species:ncbi:202950">Acinetobacter baylyi</span>
###xml 339 359 <span type="species:ncbi:83333">Escherichia coli K12</span>
###xml 361 387 <span type="species:ncbi:1773">Mycobacterium tuberculosis</span>
###xml 399 426 <span type="species:ncbi:208964">Pseudomonas aeruginosa PAO1</span>
###xml 522 529 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
We have initiated collaboration with David Eisenberg's group at UCLA. He searched the four bacterial genomes to identify genes encoding putative protein-protein complexes where one member is a predicted to be a membrane protein. We obtained a total of 42 membrane protein-containing complexes (86 proteins) from Acinetobacter baylyi ADP1, Escherichia coli K12, Mycobacterium tuberculosis H37RV, and Pseudomonas aeruginosa PAO1, were chosen as targets for CSMP. All have two subunits with the exception of one complex from E. coli, which has four protein components.
###end p 97
###begin p 98
###xml 61 68 61 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 61 68 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Our aim is to co-express members of each complex in the same E. coli cell host since co-expression may allow association during synthesis, and bring advantages of solubility, activity and stability compared to proteins expressed separately. We initially attempted an LIC Duet cloning strategy marketed by Novagen; however this method has been successful for only one complex.
###end p 98
###begin p 99
We have cloned the all of the genes on separate compatible plasmids that can be co-transformed. Expression testing is now ongoing.
###end p 99
###begin title 100
Membrane transporters (Kathy Giacomini)
###end title 100
###begin p 101
###xml 248 253 <span type="species:ncbi:9606">human</span>
###xml 474 479 <span type="species:ncbi:9606">human</span>
###xml 704 709 <span type="species:ncbi:9606">human</span>
Membrane transporters play a critical role in drug disposition and response. The Pharmacogenomics of Membrane Transporters project (PMT) is focused on discovering and functionally evaluating genetic polymorphisms in 50 membrane transporters in the human genome. These transporters are in two major super families, ATP Binding Cassette (ABC) Superfamily and Solute Carrier Superfamily (SLC). The goal of our studies in the CSMP project is to develop expression constructs of human membrane transporters in appropriate expression vectors and functional assays so that the transporters can be expressed in abundance to facilitate the determination of structures. Our laboratory clones the transporters from human and mammalian tissues and functionally characterizes the transporters in mammalian expression systems. To date, 20 transporters have been cloned and functional assays performed.
###end p 101
###begin p 102
###xml 102 107 <span type="species:ncbi:9606">human</span>
The goal of our studies in the CSMP is to develop expression and purification protocols of functional human membrane transporters for downstream structure determination and characterization. Another goal for the coming year is to develop a collaboration with Volker Dotsch in the expression and purification of membrane transporters in the Solute Carrier Superfamily (SLC). Volker has developed a non-cellular system of expression of large quantities of membrane proteins.
###end p 102
###begin p 103
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab4" ref-type="table">4</xref>
###xml 76 83 76 83 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;4</label>
###xml 83 174 83 174 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="104">Progress of transporter cloning and functional characterization in the Giacomini Laboratory</p>
###xml 83 174 83 174 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="104">Progress of transporter cloning and functional characterization in the Giacomini Laboratory</p></caption>
###xml 174 174 174 174 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"/>
###xml 174 185 174 185 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Transporter</th>
###xml 185 187 185 187 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MW</th>
###xml 187 203 187 203 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Functional clone</th>
###xml 203 219 203 219 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yeast expression</th>
###xml 219 230 219 230 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Solubilized</th>
###xml 230 238 230 238 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Purified</th>
###xml 174 238 174 238 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left"/><th align="left">Transporter</th><th align="left">MW</th><th align="left">Functional clone</th><th align="left">Yeast expression</th><th align="left">Solubilized</th><th align="left">Purified</th></tr>
###xml 174 238 174 238 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left"/><th align="left">Transporter</th><th align="left">MW</th><th align="left">Functional clone</th><th align="left">Yeast expression</th><th align="left">Solubilized</th><th align="left">Purified</th></tr></thead>
###xml 238 239 238 239 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1</td>
###xml 239 245 239 245 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hMATE1</td>
###xml 245 250 245 250 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">61919</td>
###xml 250 251 250 251 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 251 260 251 260 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~0.8&#160;mg/l</td>
###xml 260 262 260 262 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 262 264 262 264 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 238 264 238 264 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">1</td><td align="left">hMATE1</td><td char="." align="char">61919</td><td align="left">X</td><td align="left">~0.8&#160;mg/l</td><td align="left">No</td><td align="left">No</td></tr>
###xml 264 265 264 265 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">2</td>
###xml 265 271 265 271 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rMATE1</td>
###xml 271 276 271 276 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">61436</td>
###xml 276 277 276 277 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 277 286 277 286 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~0.5&#160;mg/l</td>
###xml 286 289 286 289 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 289 291 289 291 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 264 291 264 291 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">2</td><td align="left">rMATE1</td><td char="." align="char">61436</td><td align="left">X</td><td align="left">~0.5&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr>
###xml 291 292 291 292 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">3</td>
###xml 292 297 292 297 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hENT1</td>
###xml 297 302 297 302 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">50216</td>
###xml 302 303 302 303 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 303 310 303 310 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~2&#160;mg/l</td>
###xml 310 313 310 313 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 313 316 313 316 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 291 316 291 316 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">3</td><td align="left">hENT1</td><td char="." align="char">50216</td><td align="left">X</td><td align="left">~2&#160;mg/l</td><td align="left">Yes</td><td align="left">Yes</td></tr>
###xml 316 317 316 317 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">4</td>
###xml 317 322 317 322 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hENT2</td>
###xml 322 327 322 327 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">50110</td>
###xml 327 328 327 328 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 328 337 328 337 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~1.2&#160;mg/l</td>
###xml 337 341 337 341 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~50%</td>
###xml 341 344 341 344 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 316 344 316 344 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">4</td><td align="left">hENT2</td><td char="." align="char">50110</td><td align="left">X</td><td align="left">~1.2&#160;mg/l</td><td align="left">~50%</td><td align="left">Yes</td></tr>
###xml 344 345 344 345 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">5</td>
###xml 345 350 345 350 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hENT3</td>
###xml 350 355 350 355 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">51712</td>
###xml 355 356 355 356 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 356 365 356 365 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~0.8&#160;mg/l</td>
###xml 365 369 365 369 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~60%</td>
###xml 369 371 369 371 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 344 371 344 371 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">5</td><td align="left">hENT3</td><td char="." align="char">51712</td><td align="left">X</td><td align="left">~0.8&#160;mg/l</td><td align="left">~60%</td><td align="left">No</td></tr>
###xml 371 372 371 372 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">6</td>
###xml 372 377 372 377 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hCNT1</td>
###xml 377 382 377 382 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">71580</td>
###xml 382 383 382 383 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 383 392 383 392 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~1.0&#160;mg/l</td>
###xml 392 395 392 395 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 395 398 395 398 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 371 398 371 398 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">6</td><td align="left">hCNT1</td><td char="." align="char">71580</td><td align="left">X</td><td align="left">~1.0&#160;mg/l</td><td align="left">Yes</td><td align="left">Yes</td></tr>
###xml 398 399 398 399 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">7</td>
###xml 399 404 399 404 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hCNT2</td>
###xml 404 409 404 409 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">71991</td>
###xml 409 410 409 410 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 410 414 410 414 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">POOR</td>
###xml 414 417 414 417 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 417 420 417 420 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 398 420 398 420 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">7</td><td align="left">hCNT2</td><td char="." align="char">71991</td><td align="left">X</td><td align="left">POOR</td><td align="left">Yes</td><td align="left">Yes</td></tr>
###xml 420 421 420 421 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">8</td>
###xml 421 426 421 426 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hCNT3</td>
###xml 426 431 426 431 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">76925</td>
###xml 431 432 431 432 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 432 441 432 441 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~0.5&#160;mg/l</td>
###xml 441 444 441 444 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 444 446 444 446 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 420 446 420 446 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">8</td><td align="left">hCNT3</td><td char="." align="char">76925</td><td align="left">X</td><td align="left">~0.5&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr>
###xml 446 447 446 447 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">9</td>
###xml 447 453 447 453 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hOCTN1</td>
###xml 453 458 453 458 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">62151</td>
###xml 458 459 458 459 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 459 468 459 468 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~1.0&#160;mg/l</td>
###xml 468 472 468 472 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~50%</td>
###xml 472 474 472 474 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 446 474 446 474 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">9</td><td align="left">hOCTN1</td><td char="." align="char">62151</td><td align="left">X</td><td align="left">~1.0&#160;mg/l</td><td align="left">~50%</td><td align="left">No</td></tr>
###xml 474 476 474 476 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">10</td>
###xml 476 481 476 481 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hOCT1</td>
###xml 481 486 481 486 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">61150</td>
###xml 486 487 486 487 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 487 496 487 496 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~1.0&#160;mg/l</td>
###xml 496 499 496 499 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 499 501 499 501 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 474 501 474 501 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">10</td><td align="left">hOCT1</td><td char="." align="char">61150</td><td align="left">X</td><td align="left">~1.0&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr>
###xml 501 503 501 503 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">11</td>
###xml 503 508 503 508 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hOCT2</td>
###xml 508 513 508 513 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">62560</td>
###xml 513 514 513 514 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 514 523 514 523 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~0.8&#160;mg/l</td>
###xml 523 526 523 526 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</td>
###xml 526 528 526 528 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 501 528 501 528 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">11</td><td align="left">hOCT2</td><td char="." align="char">62560</td><td align="left">X</td><td align="left">~0.8&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr>
###xml 528 530 528 530 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">12</td>
###xml 530 535 530 535 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hOCT3</td>
###xml 535 540 535 540 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">61276</td>
###xml 540 541 540 541 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 541 550 541 550 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~0.5&#160;mg/l</td>
###xml 550 554 550 554 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">~60%</td>
###xml 554 556 554 556 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 528 556 528 556 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">12</td><td align="left">hOCT3</td><td char="." align="char">61276</td><td align="left">X</td><td align="left">~0.5&#160;mg/l</td><td align="left">~60%</td><td align="left">No</td></tr>
###xml 556 558 556 558 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">13</td>
###xml 558 564 558 564 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hABCG2</td>
###xml 564 569 564 569 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">72309</td>
###xml 569 570 569 570 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 570 578 570 578 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">1.0&#160;mg/l</td>
###xml 578 580 578 580 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 580 582 580 582 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</td>
###xml 556 582 556 582 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">13</td><td align="left">hABCG2</td><td char="." align="char">72309</td><td align="left">X</td><td align="left">1.0&#160;mg/l</td><td align="left">No</td><td align="left">No</td></tr>
###xml 582 584 582 584 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">14</td>
###xml 584 590 584 590 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hMATE2</td>
###xml 590 591 590 591 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8211;</td>
###xml 591 592 591 592 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 592 602 592 602 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 602 612 602 612 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 612 622 612 622 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 582 622 582 622 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">14</td><td align="left">hMATE2</td><td char="." align="char">&#8211;</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr>
###xml 622 624 622 624 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">15</td>
###xml 624 629 624 629 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hOAT1</td>
###xml 629 634 629 634 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">61812</td>
###xml 634 635 634 635 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 635 645 635 645 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 645 655 645 655 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 655 665 655 665 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 622 665 622 665 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">15</td><td align="left">hOAT1</td><td char="." align="char">61812</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr>
###xml 665 667 665 667 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">16</td>
###xml 667 672 667 672 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hOAT2</td>
###xml 672 677 672 677 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">59807</td>
###xml 677 678 677 678 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 678 688 678 688 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 688 698 688 698 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 698 708 698 708 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 665 708 665 708 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">16</td><td align="left">hOAT2</td><td char="." align="char">59807</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr>
###xml 708 710 708 710 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">17</td>
###xml 710 715 710 715 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hOAT3</td>
###xml 715 720 715 720 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">59853</td>
###xml 720 721 720 721 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 721 731 721 731 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 731 741 731 741 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 741 751 741 751 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 708 751 708 751 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">17</td><td align="left">hOAT3</td><td char="." align="char">59853</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr>
###xml 751 753 751 753 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">18</td>
###xml 753 758 753 758 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hOAT4</td>
###xml 758 763 758 763 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">62166</td>
###xml 763 764 763 764 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 764 774 764 774 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 774 784 774 784 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 784 794 784 794 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 751 794 751 794 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">18</td><td align="left">hOAT4</td><td char="." align="char">62166</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr>
###xml 794 796 794 796 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">19</td>
###xml 796 802 796 802 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">hOCTN2</td>
###xml 802 807 802 807 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">62747</td>
###xml 807 808 807 808 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 808 818 808 818 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 818 828 818 828 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 828 838 828 838 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 794 838 794 838 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">19</td><td align="left">hOCTN2</td><td char="." align="char">62747</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr>
###xml 838 840 838 840 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">20</td>
###xml 840 844 840 844 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">CTR1</td>
###xml 844 845 844 845 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#8211;</td>
###xml 845 846 845 846 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">X</td>
###xml 846 856 846 856 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 856 866 856 866 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 866 876 866 876 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Not tested</td>
###xml 838 876 838 876 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">20</td><td align="left">CTR1</td><td char="." align="char">&#8211;</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr>
###xml 238 876 238 876 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">1</td><td align="left">hMATE1</td><td char="." align="char">61919</td><td align="left">X</td><td align="left">~0.8&#160;mg/l</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">2</td><td align="left">rMATE1</td><td char="." align="char">61436</td><td align="left">X</td><td align="left">~0.5&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr><tr><td align="left">3</td><td align="left">hENT1</td><td char="." align="char">50216</td><td align="left">X</td><td align="left">~2&#160;mg/l</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">4</td><td align="left">hENT2</td><td char="." align="char">50110</td><td align="left">X</td><td align="left">~1.2&#160;mg/l</td><td align="left">~50%</td><td align="left">Yes</td></tr><tr><td align="left">5</td><td align="left">hENT3</td><td char="." align="char">51712</td><td align="left">X</td><td align="left">~0.8&#160;mg/l</td><td align="left">~60%</td><td align="left">No</td></tr><tr><td align="left">6</td><td align="left">hCNT1</td><td char="." align="char">71580</td><td align="left">X</td><td align="left">~1.0&#160;mg/l</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">7</td><td align="left">hCNT2</td><td char="." align="char">71991</td><td align="left">X</td><td align="left">POOR</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">8</td><td align="left">hCNT3</td><td char="." align="char">76925</td><td align="left">X</td><td align="left">~0.5&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr><tr><td align="left">9</td><td align="left">hOCTN1</td><td char="." align="char">62151</td><td align="left">X</td><td align="left">~1.0&#160;mg/l</td><td align="left">~50%</td><td align="left">No</td></tr><tr><td align="left">10</td><td align="left">hOCT1</td><td char="." align="char">61150</td><td align="left">X</td><td align="left">~1.0&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr><tr><td align="left">11</td><td align="left">hOCT2</td><td char="." align="char">62560</td><td align="left">X</td><td align="left">~0.8&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr><tr><td align="left">12</td><td align="left">hOCT3</td><td char="." align="char">61276</td><td align="left">X</td><td align="left">~0.5&#160;mg/l</td><td align="left">~60%</td><td align="left">No</td></tr><tr><td align="left">13</td><td align="left">hABCG2</td><td char="." align="char">72309</td><td align="left">X</td><td align="left">1.0&#160;mg/l</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">14</td><td align="left">hMATE2</td><td char="." align="char">&#8211;</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">15</td><td align="left">hOAT1</td><td char="." align="char">61812</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">16</td><td align="left">hOAT2</td><td char="." align="char">59807</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">17</td><td align="left">hOAT3</td><td char="." align="char">59853</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">18</td><td align="left">hOAT4</td><td char="." align="char">62166</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">19</td><td align="left">hOCTN2</td><td char="." align="char">62747</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">20</td><td align="left">CTR1</td><td char="." align="char">&#8211;</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr></tbody>
###xml 174 876 174 876 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Transporter</th><th align="left">MW</th><th align="left">Functional clone</th><th align="left">Yeast expression</th><th align="left">Solubilized</th><th align="left">Purified</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">hMATE1</td><td char="." align="char">61919</td><td align="left">X</td><td align="left">~0.8&#160;mg/l</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">2</td><td align="left">rMATE1</td><td char="." align="char">61436</td><td align="left">X</td><td align="left">~0.5&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr><tr><td align="left">3</td><td align="left">hENT1</td><td char="." align="char">50216</td><td align="left">X</td><td align="left">~2&#160;mg/l</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">4</td><td align="left">hENT2</td><td char="." align="char">50110</td><td align="left">X</td><td align="left">~1.2&#160;mg/l</td><td align="left">~50%</td><td align="left">Yes</td></tr><tr><td align="left">5</td><td align="left">hENT3</td><td char="." align="char">51712</td><td align="left">X</td><td align="left">~0.8&#160;mg/l</td><td align="left">~60%</td><td align="left">No</td></tr><tr><td align="left">6</td><td align="left">hCNT1</td><td char="." align="char">71580</td><td align="left">X</td><td align="left">~1.0&#160;mg/l</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">7</td><td align="left">hCNT2</td><td char="." align="char">71991</td><td align="left">X</td><td align="left">POOR</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">8</td><td align="left">hCNT3</td><td char="." align="char">76925</td><td align="left">X</td><td align="left">~0.5&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr><tr><td align="left">9</td><td align="left">hOCTN1</td><td char="." align="char">62151</td><td align="left">X</td><td align="left">~1.0&#160;mg/l</td><td align="left">~50%</td><td align="left">No</td></tr><tr><td align="left">10</td><td align="left">hOCT1</td><td char="." align="char">61150</td><td align="left">X</td><td align="left">~1.0&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr><tr><td align="left">11</td><td align="left">hOCT2</td><td char="." align="char">62560</td><td align="left">X</td><td align="left">~0.8&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr><tr><td align="left">12</td><td align="left">hOCT3</td><td char="." align="char">61276</td><td align="left">X</td><td align="left">~0.5&#160;mg/l</td><td align="left">~60%</td><td align="left">No</td></tr><tr><td align="left">13</td><td align="left">hABCG2</td><td char="." align="char">72309</td><td align="left">X</td><td align="left">1.0&#160;mg/l</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">14</td><td align="left">hMATE2</td><td char="." align="char">&#8211;</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">15</td><td align="left">hOAT1</td><td char="." align="char">61812</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">16</td><td align="left">hOAT2</td><td char="." align="char">59807</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">17</td><td align="left">hOAT3</td><td char="." align="char">59853</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">18</td><td align="left">hOAT4</td><td char="." align="char">62166</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">19</td><td align="left">hOCTN2</td><td char="." align="char">62747</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">20</td><td align="left">CTR1</td><td char="." align="char">&#8211;</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr></tbody></table>
###xml 76 876 76 876 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab4"><label>Table&#160;4</label><caption><p textid="104">Progress of transporter cloning and functional characterization in the Giacomini Laboratory</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">Transporter</th><th align="left">MW</th><th align="left">Functional clone</th><th align="left">Yeast expression</th><th align="left">Solubilized</th><th align="left">Purified</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">hMATE1</td><td char="." align="char">61919</td><td align="left">X</td><td align="left">~0.8&#160;mg/l</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">2</td><td align="left">rMATE1</td><td char="." align="char">61436</td><td align="left">X</td><td align="left">~0.5&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr><tr><td align="left">3</td><td align="left">hENT1</td><td char="." align="char">50216</td><td align="left">X</td><td align="left">~2&#160;mg/l</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">4</td><td align="left">hENT2</td><td char="." align="char">50110</td><td align="left">X</td><td align="left">~1.2&#160;mg/l</td><td align="left">~50%</td><td align="left">Yes</td></tr><tr><td align="left">5</td><td align="left">hENT3</td><td char="." align="char">51712</td><td align="left">X</td><td align="left">~0.8&#160;mg/l</td><td align="left">~60%</td><td align="left">No</td></tr><tr><td align="left">6</td><td align="left">hCNT1</td><td char="." align="char">71580</td><td align="left">X</td><td align="left">~1.0&#160;mg/l</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">7</td><td align="left">hCNT2</td><td char="." align="char">71991</td><td align="left">X</td><td align="left">POOR</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">8</td><td align="left">hCNT3</td><td char="." align="char">76925</td><td align="left">X</td><td align="left">~0.5&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr><tr><td align="left">9</td><td align="left">hOCTN1</td><td char="." align="char">62151</td><td align="left">X</td><td align="left">~1.0&#160;mg/l</td><td align="left">~50%</td><td align="left">No</td></tr><tr><td align="left">10</td><td align="left">hOCT1</td><td char="." align="char">61150</td><td align="left">X</td><td align="left">~1.0&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr><tr><td align="left">11</td><td align="left">hOCT2</td><td char="." align="char">62560</td><td align="left">X</td><td align="left">~0.8&#160;mg/l</td><td align="left">Yes</td><td align="left">No</td></tr><tr><td align="left">12</td><td align="left">hOCT3</td><td char="." align="char">61276</td><td align="left">X</td><td align="left">~0.5&#160;mg/l</td><td align="left">~60%</td><td align="left">No</td></tr><tr><td align="left">13</td><td align="left">hABCG2</td><td char="." align="char">72309</td><td align="left">X</td><td align="left">1.0&#160;mg/l</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">14</td><td align="left">hMATE2</td><td char="." align="char">&#8211;</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">15</td><td align="left">hOAT1</td><td char="." align="char">61812</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">16</td><td align="left">hOAT2</td><td char="." align="char">59807</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">17</td><td align="left">hOAT3</td><td char="." align="char">59853</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">18</td><td align="left">hOAT4</td><td char="." align="char">62166</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">19</td><td align="left">hOCTN2</td><td char="." align="char">62747</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr><tr><td align="left">20</td><td align="left">CTR1</td><td char="." align="char">&#8211;</td><td align="left">X</td><td align="left">Not tested</td><td align="left">Not tested</td><td align="left">Not tested</td></tr></tbody></table></table-wrap>
Table 4 below describes progress made in our project over the first 3 years.Table 4Progress of transporter cloning and functional characterization in the Giacomini LaboratoryTransporterMWFunctional cloneYeast expressionSolubilizedPurified1hMATE161919X~0.8 mg/lNoNo2rMATE161436X~0.5 mg/lYesNo3hENT150216X~2 mg/lYesYes4hENT250110X~1.2 mg/l~50%Yes5hENT351712X~0.8 mg/l~60%No6hCNT171580X~1.0 mg/lYesYes7hCNT271991XPOORYesYes8hCNT376925X~0.5 mg/lYesNo9hOCTN162151X~1.0 mg/l~50%No10hOCT161150X~1.0 mg/lYesNo11hOCT262560X~0.8 mg/lYesNo12hOCT361276X~0.5 mg/l~60%No13hABCG272309X1.0 mg/lNoNo14hMATE2-XNot testedNot testedNot tested15hOAT161812XNot testedNot testedNot tested16hOAT259807XNot testedNot testedNot tested17hOAT359853XNot testedNot testedNot tested18hOAT462166XNot testedNot testedNot tested19hOCTN262747XNot testedNot testedNot tested20CTR1-XNot testedNot testedNot tested
###end p 103
###begin p 104
Progress of transporter cloning and functional characterization in the Giacomini Laboratory
###end p 104
###begin title 105
Bacterial receptor kinases (SALK-Choe, Kefala)-bacterial histidine kinase receptors (SALK-Choe, Kefala)
###end title 105
###begin p 106
###xml 289 296 289 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 327 334 327 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 289 296 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 327 334 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Crystal structures of bacterial histidine kinase receptors are the main targets of our efforts. To facilitate the structure determination, we have carried out a systematic approach in selecting and constructing expression vectors of these family members. Based on the complete analysis of E. coli genome, we identified 25 such E. coli's kinase receptors, 23 of which are histidine kinase receptors and the remaining two being tyrosine kinase receptors. All these receptors are part of two-component transmembrane signaling systems.
###end p 106
###begin p 107
###xml 993 1001 <span type="species:ncbi:7460">Honeybee</span>
###xml 1034 1039 <span type="species:ncbi:9606">human</span>
###xml 1238 1243 <span type="species:ncbi:9606">human</span>
###xml 1331 1336 <span type="species:ncbi:4932">yeast</span>
We have prepared a two-prong approach in making expression constructs in order to analyze the effectiveness of Mistic fusion on protein expression. Our laboratory uses Gateway expression vector technology to construct these vectors so it is very easy of put these vectors together. One is fused with Mistic (Misticated), and the other without Mistic (non-Misticated). Both carry an octahistidine tag as an affinity tag to facilitate purification. These are further expanded by removing the putative signal sequence present in the gene, also by the addition of response regulators. This combinatorial mix of about 100 protein constructs are at various stages of the pipeline for overproduction. About 12 of those have reached the stage of well-behaving protein (grade A) purified at sufficient quantity for further work. The crystallization efforts are being made with various combinations of additives and detergents. The project utilizes significantly a high-throughput crystallization using Honeybee 96 robot in the laboratory. For human targets, we continue to optimize the high-throughput tools and vectors as well as control vectors to benchmark the progress in order to process 35 plates currently in possession, each containing 96 human targets. Lately, we have initiated a new approach using Mistic as a signal sequence of yeast expression system. All these expression vector systems rely on the Gateway technology to ease the exchange of expression vectors for a target gene.
###end p 107
###begin title 108
Bacterial secondary transporters (UCLA-Kaback): Nucleobase Cation Symporter 2 (NCS2) family
###end title 108
###begin p 109
###xml 5 6 5 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 227 228 227 228 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 665 672 665 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 674 689 674 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T. thermophilus</italic>
###xml 691 702 691 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P. furiosus</italic>
###xml 714 727 714 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T. maritimus,</italic>
###xml 750 757 750 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 795 802 795 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 807 822 807 822 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T. thermophilus</italic>
###xml 1115 1122 1115 1122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 1273 1274 1272 1273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 1276 1282 1275 1281 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 1282 1283 1281 1282 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 1387 1388 1386 1387 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
###xml 1282 1550 1281 1549 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="110"><bold>a</bold> Photomicrograph of crystals for YgfO obtained from salt-based crystallization conditions and xanthine. <bold>b</bold> Photograph of a silver stained SDS-PAGE gel showing the protein composition of the crystals harvested from the salt-based crystallization conditions and xanthine</p>
###xml 1282 1550 1281 1549 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="110"><bold>a</bold> Photomicrograph of crystals for YgfO obtained from salt-based crystallization conditions and xanthine. <bold>b</bold> Photograph of a silver stained SDS-PAGE gel showing the protein composition of the crystals harvested from the salt-based crystallization conditions and xanthine</p></caption>
###xml 1550 1550 1549 1549 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="10969_2008_9058_Fig2_HTML" id="MO2"/>
###xml 1276 1550 1275 1549 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="110"><bold>a</bold> Photomicrograph of crystals for YgfO obtained from salt-based crystallization conditions and xanthine. <bold>b</bold> Photograph of a silver stained SDS-PAGE gel showing the protein composition of the crystals harvested from the salt-based crystallization conditions and xanthine</p></caption><graphic position="anchor" xlink:href="10969_2008_9058_Fig2_HTML" id="MO2"/></fig>
###xml 665 672 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 674 689 <span type="species:ncbi:274|species:ncbi:28565">T. thermophilus</span>
###xml 691 702 <span type="species:ncbi:2261|species:ncbi:506458">P. furiosus</span>
###xml 714 726 <span type="species:ncbi:54250|species:ncbi:29073|species:ncbi:118937">T. maritimus</span>
###xml 750 757 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 795 802 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 807 822 <span type="species:ncbi:274|species:ncbi:28565">T. thermophilus</span>
###xml 1115 1122 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
The H+/nucleobase-ascorbate symporter YgfO, which belongs to the NCS2 family of transport proteins, is ubiquitously found in all cells from archaea to eukaryotes. This highly conserved family consists of purine, pyrimidine and l-ascorbate transporters, with members specific for the cellular uptake of uracil, xanthine or uric acid (microbial and plant genomes) or vitamin C (mammalian genomes), as well as several important purine-related drugs (5-fluorouracil, allopurinol, oxypurinol). Thus, a crystal structure of YgfO would be relevant to the development of anti-cancer drugs, drugs to treat gout and anti- oxidants. We cloned four members of NCS2 family from E. coli, T. thermophilus, P. furiosus as well as T. maritimus, and expressed them in E. coli DE3 strain. Well-expressed YgfO from E. coli and T. thermophilus are solubilized with Fos-choline (FC)-14, purified by IMAC (Talon resin), yielding 1-2 mg/l culture. Both proteins are stable on ice for at least 2-4 weeks. Recently, initial crystallization screening by microbatch and hanging drop vapor diffusion yielded a few 'hits' for YgfO purified from E. coli HRK43. After brief optimization, relatively large crystals (50 x 200 mum) were obtained from salt-based crystallization conditions and xanthine (Fig. 2).Fig. 2a Photomicrograph of crystals for YgfO obtained from salt-based crystallization conditions and xanthine. b Photograph of a silver stained SDS-PAGE gel showing the protein composition of the crystals harvested from the salt-based crystallization conditions and xanthine
###end p 109
###begin p 110
###xml 0 1 0 1 <bold xmlns:xlink="http://www.w3.org/1999/xlink">a</bold>
###xml 105 106 105 106 <bold xmlns:xlink="http://www.w3.org/1999/xlink">b</bold>
a Photomicrograph of crystals for YgfO obtained from salt-based crystallization conditions and xanthine. b Photograph of a silver stained SDS-PAGE gel showing the protein composition of the crystals harvested from the salt-based crystallization conditions and xanthine
###end p 110
###begin title 111
The ion transporter superfamily (ITS)
###end title 111
###begin p 112
###xml 506 513 506 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 535 536 535 536 <sc xmlns:xlink="http://www.w3.org/1999/xlink">l</sc>
###xml 542 543 542 543 <sc xmlns:xlink="http://www.w3.org/1999/xlink">d</sc>
###xml 570 571 570 571 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 882 901 882 901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neisseria gonorrhea</italic>
###xml 506 513 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Lactate permease (LctP) belongs to the ITS family found in Gram-negative and Gram-positive bacteria, as well as Archaea. All LctP members are proposed to have 14-16 transmembrane -helices with both N- and C-terminal exposed to the periplasm. We used the PhoA fusion approach where the expression construct is made with an embedded alkaline phosphatase sequence, permitting the gene expression to be easily monitored by a simple alkaline phosphatase assay. LctP appears to contain 14 transmembrane domains. E. coli LctP transports both l- and d-lactate and is a lactate/H+ symporter. It is also highly interesting that LctP is one of a group of acidic substrates that seems to be coupled to the pH gradient (interior alkaline) at ambient acidic pH values, but coupled to the membrane potential (interior negative) at more alkaline pH values. Recently, it was reported that LctP from Neisseria gonorrhea is important for pathogenesis. Crystals of LctP were obtained with PEG400/(NH4)2SO4 (pH 8.6) after several months incubation. At the ALS beamline 8.2.1, anisotropic diffraction is observed to 3.2/6.0 A and a data set was completed to 7.0 A.
###end p 112
###begin title 113
Topology of MISTIC
###end title 113
###begin p 114
###xml 25 42 25 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bacillus subtilis</italic>
###xml 120 127 120 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 172 176 172 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">phoA</italic>
###xml 245 252 245 252 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 25 42 <span type="species:ncbi:1423">Bacillus subtilis</span>
###xml 120 127 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 245 252 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
MISTIC is a protein from Bacillus subtilis that is reported to facilitate expression of eukaryotic membrane proteins in E. coli. We have utilized the alkaline phosphatase (phoA) fusion approach to study the topology of MISTIC in the membrane of E. coli. The following PhoA fusions have been constructed: MISTIC-K28, -Y58, P63, Q66, K86, G115 and T139. The letters and numbers refer to positions in MISTIC where PhoA (alkaline phosphatase) fusions were constructed. For example, K28 means that the fusion construct is MISTIC from position 1 to 28, and the rest of the fusion protein is alkaline phosphatase. In order to be active alkaline phosphatase must be translocated into the periplasm. Since none of the fusions that Lan Guan constructed-which run the length of MISTIC-have alkaline phosphatase activity, the observations would be interpreted to mean that MISTIC has no transmembrane domains. Incidentally, this is a technique that was developed originally by Manoil and Beckwith in the early '90s, and it has been used to test the hydropathy models of many polytopic membrane proteins in addition to LacY.
###end p 114
###begin title 115
Transporters and channels (Stroud)
###end title 115
###begin title 116
Ammonia channels
###end title 116
###begin p 117
###xml 118 119 118 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
Inhibitory complex of the transmembrane ammonia channel, AmtB, and the cytosolic regulatory protein, GlnK, at 1.96 A [3].
###end p 117
###begin p 118
###xml 171 178 171 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 473 475 473 475 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 171 178 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Ammonia conductance is highly regulated. A PII signal transduction protein GlnK is the final regulator of transmembrane ammonia conductance by the ammonia channel AmtB in E. coli. The complex formed between AmtB and inhibitory GlnK at 1.96 A resolution shows that the trimeric channel is blocked directly by GlnK, and how in response to intracellular nitrogen status, the ability of GlnK to block the channel is regulated by uridylylation/deuridylylation at Y51. ATP and Mg2+ augment the interaction of GlnK. The hydrolyzed product, adenosine 5'-diphosphate (ADP) orients the surface of GlnK for AmtB blockade. 2-oxoglutarate diminishes AmtB/GlnK association and plausible sites for 2-oxoglutarate binding were identified.
###end p 118
###begin p 119
###xml 43 64 43 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nitrosonomas europea.</italic>
###xml 74 95 74 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nitrosonomas europaea</italic>
###xml 674 681 674 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 301 306 <span type="species:ncbi:9606">human</span>
###xml 397 402 <span type="species:ncbi:9606">human</span>
###xml 674 681 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 998 1003 <span type="species:ncbi:9606">human</span>
Rh Sub-family of Ammonia Channels: Rh50 of Nitrosonomas europea. (Stroud) Nitrosonomas europaea is an obligate lithoautotrophic ammonia-oxidizing gram-negative bacterium. NeRh is similar to evolutionary precursors of the Rh family found in eukaryotes. It is 38% identical and has strong similarity to human Rh factors. It has been demonstrated to conduct ammonia without pH dependence seen in the human Rh channels and the mechanism is remarkably conserved to that of the Amt subfamily. Gas conduction is not yet demonstrated in our functional testing. Unlike many Rh ammonia channels, NeRh is not glycosylated. It is a trimer of 42 kDa monomers. NeRh has been expressed in E. coli obtained in pure, homogeneous and stable form. Robotic crystal trials and optimization has yielded crystals that diffracted to 2.0 A and the structure solved by molecular replacement. The refinement is complete for this structure and is a significantly better model for the structure and functional mechanism of the human channels.
###end p 119
###begin p 120
###xml 133 147 133 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. cerevisiae.</italic>
###xml 133 146 <span type="species:ncbi:4932">S. cerevisiae</span>
The Kell/KX complex is responsible for the second most common erythrocyte antigenic phenotype and we have initial over-expression in S. cerevisiae.
###end p 120
###begin p 121
###xml 76 89 76 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">S. cerevisiae</italic>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 76 89 <span type="species:ncbi:4932">S. cerevisiae</span>
Human RhCG has also been successfully expressed in the membrane fraction of S. cerevisiae and HEK293 cells, and it is soluble in OG and DDM.
###end p 121
###begin title 122
Mercury transporters (Stroud)
###end title 122
###begin p 123
###xml 172 175 172 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mer</italic>
###xml 209 211 209 211 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+2</sup>
###xml 216 224 216 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">imported</italic>
###xml 299 301 299 301 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+2</sup>
In order to survive in mercury-rich environments, bacterial mercury resistance operons utilize mercury transporting membrane proteins, specifically MerT and MerC. In these Mer systems the toxic mercury ion, Hg+2, is imported through these transporters into the cell, where it is then reduced from Hg+2 to Hg, a relatively inert elemental form of mercury. These proteins are mechanistically interesting, and they represent a novel structural family.
###end p 123
###begin p 124
###xml 86 103 86 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Shigella flexneri</italic>
###xml 223 230 223 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 86 103 <span type="species:ncbi:623">Shigella flexneri</span>
###xml 223 230 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Two bacterial mercury transporters, MerT and MerC, have been successfully cloned from Shigella flexneri into bacterial over-expression plasmid vectors as His-affinity tagged fusion proteins. Upon induction of expression in E. coli, both MerT and MerC are highly over-expressed and localized to the cell membrane, yielding approximately 4 mg of protein per liter of culture. We are near to finalizing this purification protocol and scaling up efforts to product quantities of MerT of suitable purity and low-detergent concentration for crystallization screening.
###end p 124
###begin title 125
Aquaporins (Stroud)
###end title 125
###begin p 126
###xml 34 35 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 147 158 <span type="species:ncbi:2234">A. fulgidus</span>
###xml 338 343 <span type="species:ncbi:9606">Human</span>
Aquaporins that also function in H2S transport are found in archaea. One structure has been solved for methanobacter AQPM, to 1.65 A. A second for A. fulgidus has been crystallized. The glycerol channel from the malaria parasite PfAQP has been subjected to gene design and synthesis, and has been crystallized with diffraction to 2.04 A. Human AQP4 has also been successfully been crystallized after 2 years of work and a 1.8 A dataset has been obtained. This diffraction data permitted the determination of the structure to a new higher level of resolution than before. All of these successful structure determinations are in the process of being written up for publication.
###end p 126
###begin title 127
Structure determination by Cryo EM (UCDavis-Stahlberg)
###end title 127
###begin p 128
The Stahlberg lab will continue developing the 2D membrane crystallization technology, the STEM imaging possibilities, and the maximum likelihood software tools. STEM imaging will advance due to the installation in the summer 2008 of an aberration-corrected and energy filtered 200 kV FEG STEM/TEM instrument at UC Davis, for which the Stahlberg lab is designing a new electron detector system and protocol to optimally harvest the phase contrast signal from that instrument. The Stahlberg lab is also hosting the next international workshop on electron crystallography of membrane proteins at UC Davis, which will take place Sept. 7-13, 2008 (). The Stahlberg lab continues structural investigations of a number of membrane protein systems by lipid membrane reconstitution, 2D crystallization and electron microscopy imaging trials. We have successfully reconstituted cell-free expressed CCR5 (from the Choe lab) and see first signs of structure formation within the membranes. UhpB (Choe) is reconstituted and forms first small 2D crystals. Reconstitution was successful, but so far no crystals were obtained for the sensor protein PhoQ (Choe), the lactate permease LctP (Kaback), and ABC-R (from the lab of Krys Palczewski). The Stahlberg lab also has obtained 2D crystals of a KcsA-MloK1 chimera protein, in collaboration with Crina Nimigean, NY. These crystals might reveal the KcsA gating mechanism, since the MloK1 cyclic nucleotide binding domains can activate or block the KcsA channel function. 2D crystals of the membrane embedded KscA-MloK1 chimera are obtained at different pH values, and structural analysis is ongoing. We are streamlining the process of membrane protein structure determination by electron crystallography of 2D crystals.
###end p 128
###begin title 129
2D Crystal trial volume reduction
###end title 129
###begin p 130
Current 2D crystallization trials are done by dialyzing a protein-detergent-lipid mixture of a volume of ~100 mul against detergent-free buffer. The Stahlberg lab has developed devices and a protocol for dialyzing much smaller 5 mul volumes. First results show that 2D crystallization does not scale linearly. Crystallization conditions for small and large volumes are different, and better crystals are generally obtained with larger volumes. Nevertheless, the smaller volumes allow screening a larger number of conditions with available protein material, after which the best conditions can be refined with larger volumes.
###end p 130
###begin title 131
STEM imaging
###end title 131
###begin p 132
Cryo-EM imaging of frozen hydrated and tilted specimen in the electron microscope suffers from beam-induced specimen movement or specimen charging, both of which severely limit the resolution of the structure in the direction perpendicular to the membrane plane. The Stahlberg group has compiled data that show that Scanning Transmission Electron Microscopy (STEM) is not affected by this problem, thereby bypassing the major bottleneck of electron crystallography. However, STEM imaging exposes the samples to very high dose rates of electron beam irradiation, and STEM imaging conventionally does not give phase contrast images, so that the resulting images have little contrast at lethal electron doses for the proteins. The Stahlberg lab now has developed an aberration-corrected STEM imaging protocol that allows to operate the instrument at membrane-protein compatible electron doses (5 electrons per square angstrom), and also allows access to the phase contrast signal of the electron-beam/sample interaction. The Stahlberg lab also has obtained proof of a strong phase contrast signal under the developed conditions. While it is not yet clear if the phase contrast signal is comparable to the phase contrast signal in conventional bright-field cryo-EM imaging, this development nevertheless appears likely to allow membrane protein structure analysis by cryo-EM, without the limitation from beam-induced specimen movement or charging.
###end p 132
###begin title 133
Image processing
###end title 133
###begin p 134
The Stahlberg lab continues developing new algorithms for membrane protein structure reconstruction from cryo-EM images of badly ordered 2D crystals. Realizing that the majority of the 2D crystals are not perfectly ordered, or that quasi-native membrane environments provide no crystallinity at all, such image processing will enable structure determination also from reconstituted but not crystalline membrane proteins. The Stahlberg lab is developing a single-particle 3D maximum likelihood software solution for such images, which is integrated into the user friendly 2dx software package that the Stahlberg lab is distributing ().
###end p 134
###begin title 135
Structure determination of integral membrane proteins by NMR (Salk, Riek)-small bacterial targets
###end title 135
###begin p 136
###xml 133 140 133 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 142 149 142 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink">E. coli</italic>
###xml 133 140 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
###xml 142 149 <span type="species:ncbi:110766|species:ncbi:562">E. coli</span>
Based on our structural investigations with MISTIC, we aim to determine several 3D structures of small integral membrane proteins of E. coli. E. coli has at least 52 integral membrane proteins with size smaller than 150 amino acids. Cloning and expression of all of these proteins have been initiated using MISTIC-technology in collaboration with S. Choe.
###end p 136
###begin p 137
In parallel, cloning and expression of them without MISTIC has been established in collaboration with R. Stroud. In an initial screening, four of these proteins have been selected for expression and purification. Two of them (YidH and YgaP) were expressed at 10 mg/l level, were purified by Ni IMAC and show a dimeric size based on SDS-gels and size exclusion chromatography. Extensive detergent screening was applied to both proteins. For YidH a good quality TROSY NMR spectrum was obtained and sequential assignment is in progress. For this purpose TROSY-based HNCA, HNCACB and NOESY experiments were recorded. The TROSY NMR spectrum of YgaP is not yet of good quality and further detergent screening is initiated.
###end p 137
###begin p 138
3D structure determination of corticotropin releasing factor receptor, a GPCR of family B: We aim to determine the 3D structure of corticotropin releasing factor receptor (CRF-R), a G-protein coupled receptor of family B1, by solution NMR.
###end p 138
###begin p 139
###xml 326 328 326 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 331 333 331 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
###xml 475 477 475 477 <sup xmlns:xlink="http://www.w3.org/1999/xlink">13</sup>
###xml 480 482 480 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">15</sup>
In collaboration with the Choe lab we initiated the in vitro expression of the five somatostatin receptors sst1-sst5, which belong to the family A GPCRs. The yield for ss2 and sst5 is about 1 mg/ml reaction mixture. Binding studies with its ligand somatostatin are positive and indicate that both receptors are well folded. A 13C, 15N-labeled somatostatin was synthesized in collaboration with the Rivier group (The Salk Institute) and the complex formation between sst2 and 13C, 15N-labeled somatostatin is initiated to determine the 3D structure of the ligand in complex with its receptor.
###end p 139
###begin p 140
###xml 529 530 529 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
Structural studies on KcsA potassium channel: The core of the KcsA potassium channel in its closed conformation has been determined by the MacKinnon group. We studied in detail the secondary structure as well as the dynamics of KcsA between open and closed state. It is our finding that conformational exchange dynamics between locally open and closed configurations in the filter as well as at the C-terminal end of transmembrane helix 2 are governing channel gating elucidating the mechanism of channel conductance and gating [5]. To our knowledge, this is the first study to correlate dynamics with function of a membrane protein. In addition, novel techniques are developed to study the structures and dynamics of membrane proteins.
###end p 140
###begin title 141
Summary of all structures determined
###end title 141
###begin p 142
###xml 434 455 434 455 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Nitrosomonas europaea</italic>
###xml 434 455 <span type="species:ncbi:915">Nitrosomonas europaea</span>
###xml 957 962 <span type="species:ncbi:9606">Human</span>
###xml 1284 1289 <span type="species:ncbi:9606">human</span>
The CSMP provided support during the resolution extension phase of the membrane protein Aquaporin M from Methanococcus marbergensis during Year 1, and supported the X-ray structure of the AmtB/GlnK complex (2NS1) during Year 2. The CcmG structure has been determined. It shows the ecto domain that reduces cytochromes clearly, but the transmembrane domain remains poorly determined. Refinement should define the domain A structure of Nitrosomonas europaea Rh50 has also been determined to a resolution of 1.99 A in the Stroud laboratory. In addition, we determined the structure of AcrB-an already determined structure since it was purified in its endogenous form on the Ni column due to presence of two histidines. This is a case where we determined the entire structure, in two hours after data collection, albeit only to realize that it was already determined. It was the minor contaminant of the preparation of another membrane protein of similar size! Human AQP4 is being refined currently; the dataset is of high quality, defracting to ~1.80 A. The Stahlberg laboratory obtained a 16 A structure of the bacterial membrane protein MloK1 and the structure has been deposited at the EMBD Electron Microscopy Database (5548). The Minor laboratory obtained a 2.07 A structure or the human membrane protein Kv7.4 (2OVC). The Kaback laboratory has continued to elucidate the various conditional structures of lactose permease, determining the wild type and the acidic and neutral forms (2V8 N/3.60, 2CFP/3.30, and 2CFQ/3.60, respectively.
###end p 142
###begin title 143
Open Access
###end title 143
###begin p 144
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 144
###begin title 145
References
###end title 145
###begin article-title 146
XANES measurements of the rate of radiation damage to selenomethionine side chains
###end article-title 146
###begin article-title 147
Structural basis of aquaporin inhibition by mercury
###end article-title 147
###begin article-title 148
Inhibitory complex of the transmembrane ammonia channel, AmtB, and the cytosolic regulatory protein GlnK, at 1.96 angstroms
###end article-title 148
###begin article-title 149
Structural basis for conductance by the archeal aquaporin AqpM at 1.68 angstroms
###end article-title 149
###begin article-title 150
Conformational dynamics of the Kcsa potassium channel governs gating properties
###end article-title 150

